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Our lab had previously shown that the interaction between bacterioferritin (BfrB) and its 
associated ferredoxin (Bfd) enables mobilization of iron stored in BfrB. My research was aimed 
at understanding the mechanism of the BfrB-Bfd interaction and how this interaction facilitates 
electron transfer into the ferric core in BfrB for subsequent mobilization of Fe2+ from the core. 
Results from biochemical and structural studies allowed us to conclude that the BfrB-Bfd 
interaction enables heme-mediated electron transfer from the [2Fe-2S] cluster in Bfd to the Fe3+ 
mineral stored in BfrB. The Bfd fold was revealed for the first time in the X-ray crystal 
structure of BfrB-Bfd complex. The crystal structure revealed that Bfd has a helix-turn-helix 
fold, which is distinct from the canonical ferredoxin fold. Analysis of the structure, followed by 
studies in solution showed that the [2Fe-2S] cluster in Bfd is important to stabilizing the Bfd 
fold. In addition, evidence from X-ray crystallography, in vitro assays, and in silico 
experiments, showed that Bfd is also stabilized by the binding of a phosphate anion.  The crystal 
structure of the BfrB-Bfd complex showed that 12 Bfd molecules bind a 24-mer BfrB, with 
each heme binding almost immediately above each of the 12 hemes in BfrB.  The crystal 
structure of the BfrB/Bfd complex also allowed us to identify the residues from each of the two 
proteins that participate at the complex interface, and to analyze specific interactions among 
these residues. The interaction between BfrB and Bfd was also characterized in solution by 
surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC). The results show 
Bfd binds at each of the sites on BfrB with Kd of ~ 3 µM, in an association that is driven 
entropically.  In addition, contributions of the residues that participate at the BfrB-Bfd complex 
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Antimicrobial agents, including antibiotics and similar drugs, have been used for 
treating patients with infections over the last 70 years [1]. By greatly reducing the illness and 
death from the infections, some of the antimicrobial agents that have been used as first-line 
treatments for infectious diseases are decades old. This long-time usage of antibacterial drugs in 
human therapy and in the livestock industry caused bacteria to evolve multiple mechanisms of 
antibiotic resistance, currently resistance mechanisms have been observed to all of the currently 
available antibacterial drugs [2].  The antibiotic- resistant strains have been widely spread by 
cross-infections from antibiotic treated patients and animals to the general community [3]. Each 
year in the United States, there are at least 2 million people infected with antibiotic resistant 
pathogens, leading to 23,000 deaths [1]. Some of the pathogens have evolved the ability to 
escape the effects of multiple antibiotics and hence are called multidrug resistant (MDR) strains 
[3]. The emergence of MDR strains renders huge challenges for managing infections during the 
medical procedures [4]. To solve the severe issue of antimicrobial resistance, not only new 
antibiotics are needed, but also novel targets must be identified [1].  
Pseudomonas aeruginosa is a member of the “ESKAPE” group (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter spp). These MDR strains are called “ESKAPE” to emphasize 
their ability to escape the effects of multiple antimicrobial reagents. “ESKAPE” pathogens 
account for a major percent of nosocomial infections. For example, Pseudomonas aeruginosa is 
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a Gram-negative opportunistic pathogen that can cause severe nosocomial infections in 
immuncompromised patients (i.e. causing chronic lung infections in ~90% of cystic fibrosis 
patients, burn victims and cancer patients [5]). Each year in the United States, there are 51,000 
infections caused by Pseudomonas aeruginosa. 6,700 of these infections are multidrug resistant 
and  have led to 440 deaths [1]. In an effort to contribute toward solving the issue of MDR 
infections caused by Pseudomonas aeruginosa, our group has initiated efforts aimed at 
exploring bacterial iron homeostasis as a possible target for development of novel antibiotics.  
Bacterial Iron Homeostasis 
Iron is an essential nutrient for bacteria to survive. It participates in multiple bacterial 
metabolic processes including respiration, nitrogen fixation, photosynthesis, DNA synthesis and 
repair [6, 7]. Iron is the fourth most abundant metal in the earth’s crust; however, in the 
presence of oxygen it exists as insoluble Fe3+ (~ 10-18 M at pH 7.0), leading to limited 
bioavailability for many organisms [6, 8, 9]. Pathogenic bacteria must obtain iron from the host, 
but the free iron concentration in humans is maintained extremely low (~ 10-10 M) [10]. During 
infections, the free iron level in the host is even further reduced in order to deny this nutrient to 
invading pathogens, which is a strategy called “nutritional immunity” [11-13].  In response, 
pathogens have developed sophisticated mechanisms to obtain and utilize the iron from the host 
[6, 14-17]. In addition, it has been found that increasing availability of free iron during the 
pathogen infection would result in increasing virulence [18, 19]. Based on the intense 
competition for iron between host and bacteria, bacterial iron acquisition and homeostasis are 
regarded as having high potentials to serve as new targets for antibiotic development [20-22].  
In order to approach to this goal, it is essential to gain fundamental understanding of iron 
regulation mechanisms in bacteria.   
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Bacterial iron homeostasis includes the regulation of iron acquisition, utilization and 
storage [8, 23]. Significant research has been done to improve our understanding of iron 
acquisition processes [24-27]. In comparison, knowledge is significantly more limited regarding 
the regulation of intracellular iron levels. As mentioned above, iron in the oxidized state, Fe3+, 
has very low solubility and hence low bioavailability under physiological conditions. On the 
other hand, Fe2+ is quite soluble (~0.1 M at pH 7.0). However, free Fe2+ in cells can induce 
oxidative stress by catalyzing the Haber Weiss Cycle and generate the highly toxic hydroxyl 
radical [9]:  
	
 +   →  	
 +   + .  (Reaction 1: Fenton Reactoin) 
Superoxide or other reducing agents in the cell reduce the Fe3+ back to Fe2+: 
                   . + 	
 →   + 	
                              (Reaction 2)  
Reaction 1 + Reaction 2 yield: 
 +  . →  +  . +   (Reaction 3: Haber − Weiss Reaction) 
This process is also shown in Figure 1-1. The accumulated hydroxyl radicals are highly 
reactive and can damage bacterial cells by reacting with lipids, proteins, and DNA strands in the 
cells [9]. Consequently, the free Fe2+ levels in bacterial cells are thought to be regulated at 5 ~ 
10 µM in order to avoid the occurrence of the Haber-Weiss reaction while ensuring sufficiency 
for cell activity [28].  
Bacterial Ferritin and Bacterioferritin are Regulators of Intracellular Iron Levels 
Ferritin (Ftn) and Bacterioferritin (Bfr) are classical iron storage proteins that function as 
dynamic regulators of cytosolic iron levels. As shown in Figure 1-1, under iron sufficient 
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conditions, these proteins utilize O2 and H2O2 as electron acceptors to oxidize the potentially 
toxic Fe2+. Oxidized Fe3+ is compartmentalized into these iron storage proteins in the form of 
Fe3+ mineral, avoiding formation of Fe3+ precipitates in the cytosol; under iron depleted 
conditions, these proteins accept electrons to reduce stored Fe3+ to Fe2+ and release Fe2+ to the 
cytosol for cell activities [8]. Therefore, the functions of storing and releasing iron in iron 
storage proteins allow the intracellular free Fe2+ level to be maintained by a dynamic 
equilibrium between the stored Fe3+ mineral and free Fe 2+. 
 
Figure 1-1 Schematic representation of bacterial iron homeostasis: Iron storage proteins likely 
regulate the intracellular iron levels to avoid the occurrence of the Haber-Weiss cycle (Figure 
adapted from Handbook of Porphyrin Science, Vol. 30, p136-179, 2014.).  
Ftns are found in eukaryotes and bacteria whereas Bfrs are found only in bacteria [6, 8]. 
As shown in Figure 1-2 (A) and (B), Ftns and Bfrs share structural similarities. They are made 
from 24 subunits assembling into a nearly spherical, hollow shape with 4-3-2 symmetry. The 
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internal hollow cavity can hold up to 4,500 iron atoms. The 24-mer supramolecular assembly 
has an external diameter of ~12 nm and the internal diameter of the central cavity is about 7~ 
8.5 nm. The subunit fold consists of four α-helices arranged in a 4- helix bundle with a short 
helix nearly perpendicular to the bundle [8, 29-31]. However, one significant structural 
difference between Ftns and Bfrs is that Bfrs harbor a heme group at the two-fold symmetric 
inter-subunit sites, where the heme-iron is coordinated by a methionine residue from each 
subunit (Figure 1-2 C) [8, 29, 31]. The two subunits binding heme are therefore defined as a 
subunit dimer. The heme molecules in Bfr are buried deep below the protein shell surface (~ 13 
Å) so that the heme propionates extend into the Bfr interior cavity where the Fe 3+ mineral is 
stored (Figure 1-2 D) [8, 29].  
 Ftns and Bfrs in bacteria play a significant role in the life cycle and virulence of 
pathogens. In 1999, Chen et al found that a Bfr-deficient mutant of Nisseria gonorrhoeae 
showed impaired growth under iron-limiting conditions. The mutant is also more sensitive to 
the killing by hydrogen peroxide [32]. In 2008, Expert et al. found that a mutation of the bfr 
gene in in the plant pathogen Erwinia chrysanthemi leads to impaired iron utilization and 
growth [33]. A recent study suggests the mutants of Mycobacterium tuberculosis suffer from 
iron–mediated oxidative stress toxicity and show reduced virulence in mice and guinea pig 
models of infection [34, 35] 
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Figure 1-2 Structural organization of Bfr and Ftn (Figures adapted from Ref 8) (A) 24-mer 
assembly of Pa-FtnA (PDB:3R2K) (B) 24-mer assembly of Pa-BfrB (PDB:3IS7) (C) A subunit 
dimer of Pa-BfrB harboring a heme molecule (green). (D) Heme (green) is deeply buried below 
the Pa-BfrB protein shell surface  
As mentioned above, the two key functions of Ftn and Bfr are thought to be in iron 
storage and iron mobilization. Significant advances have been made on understanding Fe2+ 
oxidation and uptake processes in Ftn and Bfr [8, 36, 37]. However, much less is known about 
their iron reduction and mobilization process[8]. For Ftn, the physiological partner or the 
protein-protein interactions that enable iron mobilized from the Ftn core remains unknown. For 
Bfr, genomic studies that have been carried out on multiple bacteria (especially Pseudomonas 
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aeruginosa), which suggested that iron mobilization from Bfr might need protein-protein 
interaction with its associated ferredoxin (Bfd) [8]. Also, previous in vitro studies on 
Pseudomonas aeruginosa Bfr (Pa-BfrB) in our group proved that Pa-Bfd is necessary in 
mobilizing iron from Pa-BfrB [38]. These indications and evidence are described below in more 
detail.  
Genomic Studies Suggest that Iron Mobilization from Bfr Requires Protein-Protein 
Interactions 
In 1989, an E.coli gene coding for a putative ferredoxin was found to be adjacent to the 
bfr gene [39]. Due to its proximity to the bfr gene and the ability of its protein product to bind a 
[2Fe-2S] cluster, which is typical of ferredoxins [40, 41], this gene was named bfd 
(bacterioferritin-associated ferredoxin). Also, a more extensive search of genomic data on 
multiple bacteria (Table 1-1) shows the bfr-bfd gene association is common to several important 
pathogens[42]. In addition, a study on the genetic response of Pseudomonas aeruginosa to iron 
starvation conditions shows that among 118 up-regulated genes by iron starvation, only two 
genes encode electron transfer proteins, bfd  (200 –fold up-regulated) and fpr (codes for 
ferredoxin NADP reductase, 3-fold up-regulated). Meanwhile, the bfr gene is down regulated 
[43].  
By mining the available genomic data, our group proposed that the BfrB and Bfd 
association is important for iron mobilization from bacterioferritin in bacteria: The up-
regulation of bfd and fpr genes, concomitant with the down-regulation of bfrB in under iron 
starvation conditions, suggested that the roles of Bfd and Fpr may be as electron carriers to 
reduce the ferric iron stored in BfrB, therefore facilitating iron mobilization [8, 38, 42].  The 
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conserved proximity of the bfr and bfd genes also suggested that Bfr and Bfd might function 
similarly in a variety of bacteria.  
Table 1-1 bfr -bfd gene proximity in several pathogens [42] (Adapted from J. Am. Chem. Soc. 
2012, 134, 13470-13481 )  
 
In Vitro Evidence of the Bfr-Bfd Interaction 
(1) Ec Bfr-Bfd Interaction 
The finding of the formation of E. Coli Bfr -Bfd complex was the first in vitro evidence 
of the Bfr-Bfd interaction [40]. Garg et al found that a Ni-IDA column pretreated with his-
tagged Bfd binds both purified Bfr and overexpressed Bfr in a cell extract. The binding was 
demonstrated to be specific by either substituting the Bfr for bovine serum albumin and 
carbonic anhydrase, or substituting the Bfd for a C-terminal His-tagged rubredoxin-like protein 
from A. Vinelandii [40]. These authors suggested that the BfrB interaction might be important 
in iron uptake by Bfr, or in the mobilization of iron stored in Bfr. The importance of Bfd in iron 
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mobilization from Bfr was postulated and demonstrated by our group using the proteins from P. 
aeruginosa [38](see below). 
(2) Pa BfrB-Bfd Interaction  
In 2009, Weeratunga et al. also demonstrated the Bfr and Bfd from Pseudomonas 
aeruginosa (Pa BfrB and Pa Bfd) form a complex. In an experiment, the Pa BfrB was mixed 
with Pa Bfd and the protein mixture was passed through a calibrated Superdex-200 column. 
The elution volumes of the peaks suggested there are about 12 Bfd molecules bound to 1 BfrB 
molecule [38].  
Pa BfrB-Bfd Interaction Model 
By mining the genomic information and the results from the in vitro studies above, our 
group proposed a model for Pa-BfrB iron mobilization (Figure 1-3). Pa-Bfd mediates electrons 
from Pa-FPR to Pa-BfrB to reduce the Fe3+ in the BfrB core to Fe2+ and the Fe2+ is 
subsequently released from the core. 
 
Figure 1-3 Model of electron transfer across the Pa-BfrB shell to reduce Fe3+ mineral and 
promote release of Fe2+ (Figure adapted from Ref 8) 
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To test this model, the fpr, bfd, and bfrB genes from P. aeruginosa were cloned and 
expressed in E. coli. The recombinant proteins were purified and characterized.  
(1) Pa-BfrB 
In common with the structure of other bacterioferritins mentioned above, Pa-BfrB is 
composed of 24 subunits. Each subunit is built of four nearly parallel α-helices with a short C’-
terminal helix almost perpendicular to the four helices bundle (Figure 1-2A). One heme 
molecule is harbored at each subunit dimer, axially coordinated by a methionine (Met52) from 
each adjacent subunit (Figure 1-2C). The heme molecules are deeply buried below the protein 
shell surface with their propionates extending into the interior cavity where the Fe3+ mineral is 
stored (Figure 1-2D) [29]. 
There is a ferroxidase center (FC) located at the middle of each four helix bundle, which 
allows the Fe2+ to be captured and oxidized to Fe3+ and stored into the hollow cavity[8,29]. As 
shown in Figure 1-4A, the ferroxidase center in Pa-BfrB coordinates two iron ions with the 
residues E51 and E127 that function as bridging ligands and the residues H52, H130, E18 and 
E94 function as capping ligands [8, 29]. The mechanism of iron uptake in Pa-BfrB has been 
proposed (Figure 1-4B) [8, 29]. The Fe2+ is captured at the FC of each subunit to form a di-
Fe(II) center. The di-Fe(II) center is oxidized to a μ-oxo/hydroxo di-Fe (III) moiety using O2 
and H2O2 as electron acceptors. The iron ions in the di-Fe (III) moiety are transported to the Pa-
BfrB internal cavity and hence allow the empty FC to be able to capture Fe2+ and start a new 
cycle [8, 29]. 
 




Figure 1-4 (A) Ferroxidase center of Pa-BfrB (Figure adapted from Ref 8). (B) Proposed iron 
uptake and oxidation mechanism in Pa-BfrB (Figure adapted from Ref 8) 
(2) Pa-Bfd 
Pa-Bfd is a 73 amino acid protein that harbors a [2Fe-2S] cluster. Its sequence has four 
conserved cysteines: C4, C6, C38 and C41. These four cysteines are thought to coordinate the 
[2Fe-2S] cluster, which is a typical electron carrier. Until my current work (see Chapter 2), the 
structure of Bfd remained unknown [44].  
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(3) Pa-FPR 
Pa-Fpr is a nicotinamide adenine dinucleotide phosphate (NADPH)-dependent flavin-
containing enzyme, which is also thought to transfer the electrons required by Pa-heme 
oxygenase for the oxidative breakdown of heme into biliverdin and free iron [44] 
Pa-Bfd Facilitates the Mobilization of Core Iron from Pa-BfrB 
To test the Pa-BfrB iron mobilization model mentioned above, Pa-BfrB containing 600 
iron atoms in its interior cavity was mixed under anaerobic conditions with Pa-Bfd and Pa-Fpr 
in a cuvette containing excess 2’2-bipyridine (bipy) [38]. The reaction was initiated by adding 
excess NADPH.  Mobilization of iron from Pa-BfrB was monitored by tracking the time-
dependent formation of the [Fe(bipy)3]2+ complex, which absorbs at 523 nm. The percentage of 
iron release was obtained by normalizing the ΔA523 to the total absorbance change expected 
upon removal of all iron ions from Pa-BfrB. The black and red circles in Figure 1-5A indicate 
that only in the presence Pa-Bfd the iron mobilization can be facilitated [38]. Clearly, Pa-Bfd is 
necessary for the efficient and quantitative release of Fe2+. 
It is also noteworthy that during the Pa-Bfd-facilitated rapid release of iron, the heme 
Soret band from BfrB shifts from 418 nm (oxidized heme) to 425 nm (reduced heme), 
indicating full reduction of the heme in Pa-BfrB (Figure 1-5B black trace) [38]. In contrast, the 
Soret band remains unchanged in the absence of Pa-Bfd, indicating the heme remains oxidized 
(Figure 1-5B red trace). This concomitant reduction of heme only in the presence of Pa-Bfd 
agrees with the proposed model in the respect that Pa-BfrB heme accepts electrons from Pa-
Bfd. However, more experimental support was needed in order to validate the conductive nature 
of heme in the iron mobilization process [38]. 
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Figure 1-5 Binding of Pa-Bfd is necessary to promote Fe2+ mobilization from Pa-BfrB. (A) 
Normalized iron release from Pa-BfrB in the presence of Pa-Bfd (black) and without Pa-Bfd 
(red). (B) Time-dependent changes in the heme Soret band position upon the addition of 
NADPH in the presence of Pa-Bfd (black) and in the absence of Pa-Bfd (red).  
Heme Mediates Electrons to the BfrB Ferric Core 
The hypothesis, heme mediating electron transfer from the surface to the Fe3+ mineral, 
was further proved in a similar iron mobilization experiment [38]. Instead of adding extra 
NADPH, aliquots delivering 15% NADPH of the total electron equivalents required to reduce 
all the stored iron in BfrB were added. A rapid and quantative release of Fe2+ corresponding to 
the added electrons upon each addition of NADPH was observed (blue trace in Figure 1-6) [38]. 
It was also observed that the Soret band shifted rapidly from 418 nm toward 425 nm and 
gradually shifted back to 418 nm, indicating a buildup of reduced heme followed by the re-
oxidation (red trace in Figure1-6) [38]. This reducing/re-oxidizing process of heme not only 
suggests that heme mediates electrons from Pa-Bfd to the Pa-BfrB core, but also indicates that 
the Pa-Bfd transfers electrons to heme faster than heme shuttles electrons to the core mineral. 
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As the addition of NADPH aliquots proceeded, the concentration of the accumulated reduced 
heme increased. This suggested that with more Fe2+ being released, the shrinking Fe3+ core has 
less demand of electron flux from the heme. Hence, if the electron flux from Pa-Bfd to the 
heme in BfrB remains similar after each addition of NADPH, but the electron flux from the 
heme to the iron core becomes less, there is a higher transient buildup of reduced heme [8, 38]. 
 
Figure 1-6 Pa-Bfd facilitates heme mediated electron transfer to the Pa-BfrB ferric core. Time-
dependent wavelength shift of the heme Soret band (red) and time–dependent increases of A523 
upon the addition of each aliquot of NADPH (blue) (Figure adapted form Ref 38) 
The first indication that heme serves as an electron mediator in the iron mobilization 
process was obtained from stopped-flow studies with Azotobacter vinelandii Bfr (Av-Bfr) by 
Richards et al. [45]. In this study, Av-Bfr iron core was reduced with sodium dithionite and the 
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release of Fe2+ was monitored by measuring the formation of [Fe(bipy)3]2+. The oxidation state 
of heme was monitored using stopped flow experiments. The biphasic kinetics observed in the 
stopped-flow experiments suggested that heme is reduced first and then core iron is reduced by 
the electrons transferred from heme[45]. Also, a more recent study with Ec-Bfr shows that Ec-
Bfr with 5 heme/24-mer protein has a higher iron release rate upon the addition of sodium 
dithionite than the Ec-Bfr with 1 heme/24-mer protein [46]. These phenomena are in agreement 
with the notion that heme mediates electron transfer from Bfd to the Bfr core mineral [46]. 
In summary, the results above indicate: (i) the heme in bacterioferritin mediates electron 
transfer to the iron core; (ii) the interaction of Pa-BfrB and Pa-Bfd is a prerequisite for making 
the heme in BfrB “conductive”. Hence,the model proposed by our group for iron mobilization 
from BfrB (Figure 1-3) is partially supported by the above described results. Nevertheless, 
details pertaining the mechanism of the BfrB-Bfd interaction, as well as the electron transfer 
process, including the role of the Bfd [2Fe-2S] cluster, remain to be explored. These issues have 
been addressed by my work and the results will be presented throughout this dissertation. 
Role of [2Fe-2S] Cluster in BfrB Iron Mobilization 
Previously, Weeratunga et al. tried to probe the role of the [2Fe-2S] cluster during the 
BfrB iron mobilization process [38]. In the assay, the [2Fe-2S] cluster was removed from the 
Bfd in situ to make apo-Bfd, which was not separated from free Fe2+ and S2-. This solution 
containing apo-Bfd and free Fe2+ and S2- was used to investigate whether apo-Bfd can function 
in the mobilization of iron from BfrB. As shown in Figure 1-7, the apo-Bfd shows similar 
stimulatory effect as the holo-Bfd in facilitating mobilization of iron from BfrB. This 
phenomenon led the authors to propose that the [2Fe-2S] cluster was not important in this iron 
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mobilization process, and therefore the Bfd might not be participating in the electron transfer 
process as proposed in the model.  
 
Figure 1-7. Apo-Bfd (made in situ) facilitates BfrB iron mobilization (blue) in a way similar as 
holo-Bfd (red). Without Bfd, the iron mobilization from BfrB is slow (black) (Figure adapted 
from Ref 38) 
Consequently, an alternative model was proposed (Figure 1-8), where the apo-Bfd 
functions in facilitating electron transfer from FPR to BfrB by recruiting FPR to the BfrB 
surface. Clearly, this model had to be challenged rigorously by preparing and isolating apo-Bfd 
prior to reconstituting it with Pa-BfrB and Pa-FPR. In Chapter 2, I will describe how I carried 
out this work, which led to the unambiguous conclusion that the [2Fe-2S] cluster in Bfd is 
necessary to transfer electrons to the heme in BfrB [42],  
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Figure 1-8. Proposed model for BfrB iron mobilization where the electron transfer of FPR to 
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Research Problem and Rationale 
Bacterial iron homeostasis is essential for bacteria to survive, thus iron homeostasis 
provides a potential novel target for antibiotic development. To progress toward this goal, a 
molecular level understanding of how iron is regulated in bacterial cells is crucial.  Protein-
protein interactions play an important role in bacterial iron homeostasis. More specifically, the 
BfrB-Bfd interaction has been shown to facilitate iron mobilization from the BfrB in 
Pseudomonas aeruginosa [8, 38]. However, as mentioned earlier, the detailed mechanisms of 
the BfrB-Bfd interaction and the electron transfer pathway of iron mobilization were unknown. 
Consequently, our studies were focused on evaluating the two models of iron mobilization from 
BfrB to identify the most likely mechanism of iron mobilization from BfrB, characterizing the 
BfrB-Bfd interaction, and identifying the protein-protein interaction hotspot in solution. This 
fundamental work has been important to inform other activities in our lab, which are concerned 
with developing small modulators that interfere with the BfrB-Bfd interaction in order to disrupt 
the iron regulation in Pseudomonas aeruginosa. In the long-term, the significance of the BfrB-
Bfd interaction and the potential of inhibitors to disrupt the interaction will be tested in 
Pseudomonas aeruginosa cells and in vivo models of infection.  
More specifically, the first aim of my work was focused on understanding the functional 
role played by the [2Fe-2S] cluster in Bfd in iron mobilization from BfrB, because it determines 
which of the two models that had been previously proposed provides a more reasonable 
mechanism. As will be shown in Chapter 2, apo-Bfd was prepared and isolated, and the pure 
protein was biochemically characterized using UV-vis and CD spectroscopy. To elucidate the 
participation of the [2Fe-2S] cluster in iron mobilization from BfrB, apo-Bfd was used for 
mobilizing iron stored in BfrB. Upon confirming that the [2Fe-2S] cluster is required for 
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mobilizing iron stored in BfrB, we used biochemical assays to define the specific function of the 
[2Fe-2S] as an electron carrier to transfer electrons to heme in BfrB. These results, together 
with the x-ray crystal structure of the BfrB-Bfd complex, which shows that the [2Fe-2S] cluster 
is placed close to the heme in BfrB, showed that the [2Fe-2S] cluster in Bfd functions in the 
transfer of electrons to heme in BfrB. In addition, the Bfd fold was revealed for the first time in 
our X-ray crystal structure of the BfrB/Bfd complex. Details regarding these findings are 
presented in chapter 2. The solution of X-ray crystal structure of BfrB-Bfd complex provided us 
with insights into the interaction interface and allowed us to analyze the specific interactions 
among the residues at the interface. Further, to corroborate some of the findings from the X-ray 
crystallography, we studied the BfrB-Bfd interaction in solution using surface plasmon 
resonance (SPR) and isothermal titration calorimetry (ITC), as described in chapter 3. These 
studies provided thermodynamic and kinetic parameters of the interaction. In order to identify 
the contribution of the important interacting residues at the BfrB-Bfd interface suggested by the 
x-ray crystal structure of the BfrB-Bfd complex, we mutated these residues to Ala and studied 
their binding affinity and functional activity in solution. Results obtained from these studies 
were used in our lab to design and screen a fragment library, with the goal of discovering 
inhibitors of the BfrB-Bfd interaction. My familiarity with the BfrB-Bfd interaction allowed me 
to contribute to these studies by optimizing an assay directed at evaluating the efficiency of 
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CHAPTER II 
Characterizing the Structure and Function of Pa-Bfd 
Introduction 
Iron sulfur clusters are ubiquitous and versatile prosthetic groups that sustain 
fundamental life activities in most of the life forms. A variety of types of iron sulfur clusters 
including [2Fe-2S], [3Fe-4S], [4Fe-4S], [8Fe-7S] and [8Fe-8S], are found in different proteins 
with various functions. Due to their versatile chemical/electronic features, these clusters 
participate in many processes crucial to life, including electron transfer, iron/sulfur storage, 
substrate binding/activation, gene expression and regulation and enzyme activity [1, 2].  
Ferredoxins are small, soluble, mostly acidic iron sulfur proteins found universally in 
biological organisms [3]. They harbor iron sulfur clusters which possess a high negative redox 
potential. The iron sulfur clusters in ferredoxins mainly include [2Fe-2S], [3Fe-4S] and [4Fe-
4S] clusters, which typically function as electron mediators participating in a variety of 
metabolic process [2-4] .  
Among different types of iron sulfur clusters, the [2Fe-2S] cluster is the simplest 
structural-functional motif observed in ferredoxins. It consists of two iron ions bridged by two 
sulfide ions. In ferredoxins, the iron in the [2Fe-2S] cluster is coordinated by four thiolate sulfur 
centers from four cysteinyl residues. The iron centers are tetrahedral (Figure 2-1).  Sequence 
alignment of the [2Fe-2S] ferredoxins (Figure 2-2) shows that there are four conserved 
cysteines arranged in a conserved fold (C-X5-C-X2-C-X37-C), which bind the [2Fe-2S] cluster 
[4].  
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Figure 2-1 [2Fe-2S] cluster coordinated by four cysteines.   
 
Figure 2-2 Sequence alignment of different types of ferredoxins (Adapted from J Bioenerg 
Biomembr, 1994. 26(1): p. 67-88).  
The [2Fe-2S] cluster functions as a one electron oxidation/reduction site in [2Fe-2S] 
ferredoxins: in the oxidized state, both iron ions adopt the Fe3+ state, while in the reduced state 
only one of the iron ions is reduced to Fe2+ [4]. The electron transfer function of the [2Fe-2S] 
ferredoxins takes place in a variety of life activities. For example, the “plant type” ferredoxins 
(Spirulina platensis ferredoxins and Anabaena 7120 vegetative ferredoxins) transfer electrons 
from photosystem I to ferredoxin-NADP+ reductase (FNR). Anabaena 7120 Heterocyst 
ferredoxins (also a “plant type” ferredoxin) transfer electrons to the iron-protein of nitrogenase 
and hence play a role in nitrogen fixation. “Vertebrate type” ferredoxins (human placental and 
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bovine adrenal) transfer electrons from NADPH-dependent ferredoxin reductase to the 
cytochrome P450 enzyme. The ferredoxin from Pseudomonas putida (a “bacterial type” 
ferredoxin) specifically reduces the cytochrome P450cam isolated from the same species [4].   
UV-vis spectroscopy is the simplest way to identify the existence of an oxidized [2Fe-
2S] cluster.  As shown in Figure 2-3, the oxidized [2Fe-2S] cluster in typical ferredoxins causes 
bands ranging from 300 to ~ 500 nm [5]. However, the reduction of the [2Fe-2S] cluster causes 
disappearance of these characteristic bands.  
 
Figure 2-3 Example UV-vis spectra of [2Fe-2S] cluster ferredoxins ((Adapted from J Biol 
Chem, 1992. 267(16): p. 11120-5). 
Besides ferredoxins, the [2Fe-2S] cluster is also observed in nitrogenase, the redox-
sensitive transcriptional activator SoxR, the DNA-binding transcriptional regulator IscR, etc [4]. 
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Bacterioferritin associated ferredoxin (Bfd) is a small protein (50~80 residues) whose 
gene is adjacent to the bfr gene. Similar to canonical [2Fe-2S] ferredoxins, Bfd also binds a 
[2Fe-2S] cluster, which is thought to be coordinated by four conserved cysteines [6]. The UV-
vis spectrum of Pa-Bfd is shown in Figure 2-4.  
 
Figure 2-4 UV-vis spectrum of isolated Pa- Bfd with oxidized [2Fe-2S] cluster shows four 
characteristic peaks at 334 nm, 424 nm, 465 nm and 560 nm  
Alignment of Bfd sequences from different bacterial species shows the four conserved 
cysteines arranged in a C-X-C-X31-32-C-X2-C fold (Figure 2-5), which is different from the 
conserved cysteine arrangement in canonical [2Fe-2S] ferredoxins [7]. In addition, Bfds are 
generally 50 residues shorter than canonical ferredoxins. The unique arrangement of Cys 
residues in the sequences, together with the shorter length of Bfds, suggest that Bfds do not 
belong the canonical ferredoxin family. In addition, the EPR and vibrational features of Pa-Bfd 
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are more similar to the features of NifU, which is a multi-domain protein for assembling metallo 
clusters in nitrogenase [6]. These observations, together with the above-described phenomenon 
that apo-Bfd made in in situ facilitated iron mobilization from Pa-BfrB (described in Chapter 1), 
it was proposed that Pa-Bfd might function as a scaffold for [2Fe-2S] cluster assembly, rather 
than as an electron carrier. However, more experimental data is needed to support this proposal. 
 
Figure 2-5 Alignment of Bfd sequence in different bacteria shows that there are four conserved 
cysteines (red) arranged in C-X-C-X31-32-C-X2-C fold (Figure adapted from Ref 7) 
As discussed in Chapter 1, one of the key factors for understanding the BfrB-Bfd 
interaction mechanism is to determine the function of the [2Fe-2S] cluster during the Bfd-
facilitated iron mobilization process. Therefore, in the experiments described in this chapter, we 
used biochemical assays to clearly define the role of the [2Fe-2S] cluster in iron mobilization 
from BfrB. In addition, we describe the structure of the BfrB-Bfd complex, which revealed 
detailed information of the BfrB-Bfd interface and thus provides us with useful information in 
establishing the BfrB-Bfd interaction mechanism.  
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Experimental Procedures 
Pa-BfrB and the C43S mutant of Pa-Bfd were prepared and purified as reported 
previously [7].Since the same spectroscopic and functional properties were observed with C43S 
mutant compared to wild type, and the C43S mutant is more stable to purification storage and 
manipulation [7].  In this chapter, the C43S mutant will be referred to as Pa-Bfd. 
Preparation of Apo-Bfd 
A 0.54 mM solution of Pa-Bfd in 50 mM potassium phosphate (pH 7.0), 150 mM NaCl, 
and 5 mM DTT was diluted 8 times in buffer 1, consisting of sodium acetate buffer (150 mM, 
pH 5.5) 8 M urea, 150 mM NaCl, 5 mM tris(2- carboxyethyl)phosphine (TCEP), and 3 mM 
N,N′-di-(2- hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) [8]. The resultant 
solution was stirred continuously at room temperature for 70 min. Iron chelated by HBED was 
removed by dialysis against buffer 1 at room temperature. HBED was then removed by dialysis 
against buffer 1 without the chelator, and the apo-protein was then dialyzed against buffer 2 
(200 mM potassium phosphate, 8 M urea, 5 mM TCEP, pH 7.0) at room temperature. Refolding 
of apo-Bfd was carried out in two steps by dialyzing the protein against buffer 2 containing 4 M 
urea at 4 °C and then against buffer 2 without urea at 4 °C [8] 
BfrB iron release study with apo-Bfd 
The BfrB iron mobilization experiment was carried out in the presence of the isolated 
apo-Bfd.  A previously described method was used with slight modifications [7]. In an 
anaerobic chamber, the isolated apo-Bfd (10 µM), Fpr (10 µM), BfrB (0.25 µM) were mixed in 
a cuvette containing 3 mM 2’2 –bipyridyl. The reaction was initiated by addition of 1.5 mM 
NADPH.  Mobilization of iron from Pa-BfrB was monitored by tracking the time-dependent 
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formation of the [Fe(bipy)3]2+ complex, which absorbs at 523 nm [8]. The iron release percent 
was obtained by normalizing the ΔA523 to the total absorbance change expected upon removal 
of all iron ions from Pa-BfrB. The experiment was repeated by adding (NH4)2Fe(SO4)2  (20 µM) 
and Na2S (20 µM) with the apo-Bfd to the system. Also, the experiment was repeated with holo-
Bfd as a control [8]. 
Pa-Bfd transfers electrons to Pa-BfrB  
A 30 μM solution of Pa-Bfd in 20 mM phosphate buffer pH 7.6 was placed in a cuvette. 
The Pa-Bfd solution was treated with 0.8 equiv of sodium dithionite and the reduction process 
was monitored by UV-vis spectrum. The spectrum was monitored (~15min) until no further 
changes took place. A small volume of a solution containing Pa-BfrB reconstituted with 590 Fe 
atoms/BfrB and a small volume of EDTA solution were added to produce a final Pa-BfrB 
concentration of 0.08 μM and final EDTA concentration of 0.1 mM. The EDTA was added to 
prevent precipitation of ferrous phosphate, which also causes protein precipitation and drift of 
the spectral baseline [8].  
To monitor the iron release process during the reaction above, a similar experiment was 
carried out. However, instead of adding EDTA, 3 mM bipy was added prior to the addition of 
BfrB. The time dependent change in intensity at 523 nm was monitored [8].  
Removal of phosphate from Pa- Bfd 
A 780 µM solution of Pa-Bfd stock in 50 mM potassium phosphate, 150 mM NaCl, 5 
mM Dithiothreitol (DTT), pH 7.0 was diluted up to 40 times into 150 mM Tris-Base, 250 mM 
NaCl, 3 mM TCEP (tris(2-carboxyethyl)phosphine). The dilution was made in a cuvette and the 
solution was monitored by UV-vis spectroscopy up to 4 hrs. 
Removal of phosphate from Pa- Bfd in presence of Zn2+ 
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A 780 µM solution of Pa-Bfd stock in 50 mM potassium phosphate, 150 mM NaCl, 5 
mM Dithiothreitol (DTT), pH 7.0 was diluted up to 40 times into 150 mM Tris-Base, 150 mM 
NaCl, 5 mM TCEP, 125 µM ZnSO4.7H2O), pH 7.8. The dilution was made in a cuvette and the 
solution was monitored by UV-vis spectroscopy for 30min. The resulted protein was dialyzed 
against 150 mM Tris-Base, 150 mM NaCl, 5 mM TCEP, 125 µM (ZnSO4.7H2O), pH 7.8 for 
3hrs. The final product was measured for iron content using a previously described method [9] 
and the ratio of iron/protein was calculated.  
Characterization of Pa-Bfd, Pa apo-Bfd in phosphate buffer and in Tris-Base buffer by 
Circular Dichroism Spectroscopy 
Pa-Bfd was dissolved in 50 mM potassium phosphate pH 7.0, 4 mM NaCl, and 0.13 mM 
DTT. To obtain the CD spectra of Pa apo-Bfd in phosphate buffer and in Tris-Base buffer 
respectively, the following steps are used.   As mentioned above, the Bfd was unfolded in 8 M 
urea in order to make apo-Bfd. The apo-Bfd was divided into two aliquots and was refolded by 
two separate dialysis against: (1) 200 mM potassium phosphate, 3 mM TCEP, pH 7.0 and (2) 
200 mM Tris-Base, 200 mM NaCl, 3 mM TCEP, pH 7.0. To obtain good CD signal, the 
concentration of the TCEP was reduced to 1 mM and the concentration of the NaCl was reduced 
to 120 mM during the last step of dialysis, right before taking the CD spectra.  The CD spectra 
of the proteins in phosphate buffer and in Tris-Base buffer were recorded on a ChirascanTM Plus 
CD spectrometer (Applied Photophysics). Both samples were recorded at 4 °C and were 
scanned from 180 to 260 nm using a 0.05 cm bandwidth cuvette. The mean residue 
ellipticity θ (deg cm2 dmol-1 residue-1) was obtained using the Pro Data Software Suite. 
Crystallization of Pa BfrB-Bfd complex  
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A 40 µM solution of Pa-BfrB in 100 mM potassium phosphate, 1mM TCEP, pH 7.6 and 
a 480 µM solution of Pa-Bfd in 50 mM potassium phosphate, 150 mM NaCl, 5 mM 
dithiothreitol (DTT), pH 7.0 were mixed in a volume ratio of 1:1. Therefore, the final molar 
ratio of Bfd to BfrB is 12:1 [8]. 
1 µL of the protein solution and 1 µL of the crystallization solution were equilibrated 
against 100 µL of the latter in sitting drop vapor diffusion plates at 18 °C. Crystals were grown 
under aerobic conditions. Small prismatic crystals were obtained in 1-2 days with condition G8 
(0.8M Na/K hydrogen phosphate, pH7.5) of the Proplex HT screen (Molecular Dimensions) [8] 
Truncation of Pa-Bfd (M1-L56) 
The Pa-Bfd was truncated after L56. Codons coding for residue Q57 (CAG) were 
mutated to a stop codon (TAA). The sequences of the primers were designed for the truncated 
Bfd: 
Forward: 5' GAAACCCTGAACGACCTGTAAAGCGCGCAGCCGGTGCCGG 3' 
Reverse: 5' CCGGCACCGGCTGCGCGCTTTACAGGTCGTTCAGGGTTTC 3' 
The GC content is 65% and the melting temperature is 83.3 °C. 
The mutation was introduced with the aid of the Quick Change mutagenesis kit 
(Stratagene, La Jolla, CA) using manufacturer instructions. The pET11a plasmid harboring the 
gene coding for the full length Pa- Bfd was used as the template DNA. The resultant gene was 
transformed to E. coli XL1 Blue supercompetent cells for DNA amplification. Once the 
truncation was confirmed by sequencing (ACGT Inc. Wheeling, IL), plasmids carrying the 
truncated gene was transformed into E. coli Arctic express (DE3) RIL competent cells (Agilent 
Technologies, Santa Clara, CA). 
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The truncated Bfd was expressed and purified with the same method used for the full 
length Pa- Bfd. The purity of the protein was determined by SDS-PAGE. The truncation was 
confirmed by mass spectrometry. 
Crystallization of truncated-Bfd  
Purified Bfd (M1-L56) was concentrated to ~1.2 mM. During the concentration process, 
needle-shaped crystals were observed forming.  The crystallized material was removed by 
spinning down the protein solution. The supernatant was screened for crystallization Compact 
Jr. (Emerald Biosystems) sitting drop vapor diffusion plates at 20 oC using 0.5 µL of protein in 
buffer containing 50 mM potassium phosphate, 150 mM NaCl, 5 mM DTT, pH 7.0 and 0.5 µL 
of crystallization solution equilibrated against 100 µL of the latter. The supernatant containing 
small crystals was used as seeds for the subsequent crystallization trials. Needle-shaped crystals 
were observed from various conditions within an hour and grew to their maximum size in 
approximately 24 hours.  Crystals obtained from Crystal Screen HT (Hampton Research) 
condition A1 (30% (v/v) 2-methyl-2, 4-pentanediol, 100 mM sodium acetate pH 4.6, 20 mM 
CaCl2) were used for X-ray data collection. Crystals were transferred to a fresh drop of 
crystallization solution and was flash frozen in liquid nitrogen for data collection.  Data were 
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Results 
Characterizations of apo-Bfd  
Isolated apo-Bfd was characterized by mass spectrometry, UV-vis and CD spectroscopy. 
The mass spectrum of apo-Bfd shows that the molecular weight of the apo-protein is similar to 
the holo-Bfd (7807 ± 1 Da) (Figure 2-6).   
 
Figure 2-6 Mass spectrum of isolated apo-Bfd. 
The UV-vis spectrum of apo-Bfd in Figure 2-7A shows only a 280 nm band (red trace). 
Clearly, the disappearance of the characteristic peaks of the [2Fe-2S] cluster (300 nm ~ 600 nm) 
suggest successful removal of the [2Fe-2S] cluster. The far UV-CD spectra of holo-Bfd (blue) 
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and apo-Bfd (black) are shown in Figure 2-7B. The holo-Bfd has double minima at 222 and 208 
nm ([θ]222/ [θ]208 =  R∼ 1.1), representing typical α-helical structure. Compared to the holo-Bfd, 
the apo-Bfd shows decrease in intensity at the 222 nm and blue shift of the high-energy band 
from 208 nm toward 203 nm, resulting in a ratio of [θ]222/ [θ]203 =  R∼ 0.45.  
 
Figure 2-7 (A) UV-vis spectra of Pa-Bfd in 50 mM potassium phosphate pH 7.0 (black) and 
apo-Bfd in 200 mM potassium phosphate pH 7.0 and 5 mM TCEP (red) [8]. (B) Far UV CD 
spectra of Pa-Bfd in  50 mM potassium phosphate pH 7.0, 4 mM NaCl, and 0.13 mM DTT 
(blue) and Pa apo-Bfd in 200 mM Tris, pH 7.0, 120 mM NaCl and 1 mM TCEP (black) [8]. 
The CD spectral changes caused upon removal of the [2Fe-2S] cluster indicate partial 
loss of the α-helical structure [8], which suggests that the [2Fe-2S] cluster is crucial for 
stabilizing the Bfd fold. 
The role of the [2Fe-2S] cluster in the Mobilization of Iron from BfrB 
(1) Apo-Bfd in BfrB iron mobilization 
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As mentioned in Chapter 1, determining the function of the [2Fe-2S] cluster in the BfrB-
Bfd iron mobilization is crucial for exploring the detailed mechanism of this process[7, 
8].Therefore, we used our isolated apo-Bfd in the assay for measuring iron mobilization from 
Pa-BfrB. Unlike in the presence of holo-Bfd, no efficient iron release was observed in the 
presence of apo-Bfd (Figure 2-8 blue trace). However, significant acceleration of iron release 
resulted when apo-Bfd was added into the system with Fe2+ and S2- (Figure 2-8 black trace). In 
contrast, when apo-Bfd was absent, the rate of iron mobilization was sluggish, even with the 
presence of the Fe2+ and S2-. (Figure 2-8 red trace). These observations not only demonstrate 
that the [2Fe-2S] cluster is essential for mobilizing iron from Pa-BfrB, but also suggest that the 
Fe2+ and S2- might be able to readily assemble into a [2Fe-2S] cluster on apo-Bfd when BfrB is 
present. In the absence of BfrB, however, assembly of a [2Fe-2S] cluster in Bfd is slow and less 
efficient [6]. These observations also explain the phenomenon observed in the previous study 
[7] where apo-Bfd made in situ, not being separated from the Fe2+ and S2-, was able to assemble 
an iron sulfur cluster, and therefore facilitated iron release from Pa-BfrB [7].  
My experiments, therefore, prove that the [2Fe-2S] cluster in Bfd is required for 
mobilizing iron stored in BfrB. Consequently, this finding provides crucial information to 
evaluate the two models of iron mobilization discussed in Chapter 1. Model 2 can be rejected 
based on the result that the Pa apo-Bfd does not promote iron release from Pa-BfrB. In contrast, 
model 1, which indicates that holo Pa-Bfd mediates electron transfer from FPR to heme is 
supported by our experiments, and we suggest that the [2Fe-2S] cluster in Bfd functions as an 
electron mediator, to transfer electrons to the BfrB heme. 
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Figure 2-8 Time dependent increase of Pa-BfrB iron release percentage containing: (blue) Pa-
BfrB 0.25 µM), Pa-FPR (10 µM), and apo Pa-Bfd (10 µM). (black) Pa-BfrB (0.25 μM), Pa-FPR 
(10 μM), apo-Pa-Bfd (10 μM), (NH4)2Fe(SO4)2 (20 μM), and Na2S (20 μM); (red)  Pa-BfrB 
(0.25 μM), Pa-FPR (10 μM), (NH4)2Fe(SO4)2 (20 μM), and Na2S (20 μM)  
(2) The [2Fe-2S] cluster in Bfd transfers electrons to the heme in BfrB  
In order to test our hypotheses that the [2Fe-2S] cluster in Bfd mediates electrons to the 
heme in BfrB [8], a solution of holo-Pa-Bfd (30 µM) in a cuvette was reduced under anaerobic 
conditions by addition of 0.8 equiv of sodium dithionite [8]. The reduction was confirmed by a 
significant decrease in intensity of the UV-vis bands characteristic of an oxidized [2Fe-2S] 
cluster (Figure2-9A). The solution of reduced Bfd was then mixed with BfrB that had been 
reconstituted with ~590 iron, and the reaction proceeded with the spectral changes shown in 
Figure 2-9B. The red trace corresponds to Bfd with the reduced [2Fe-2S] cluster. After the 
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addition of Pa-BfrB, the Soret band in BfrB shifts from 418 nm to 424 nm within 20 s (blue 
trace), indicating reduction of the heme. Simultaneously, the characteristic peaks of the oxidized 
[2Fe-2S] cluster at 334 nm and 465 nm start to reemerge, indicating that the [2Fe-2S] cluster is 
being reoxidized. The shift in the Soret band (reduction of heme) which occurs concomitantly 
with the reemerging of the peaks characteristic of an oxidized [2Fe-2S] cluster indicate that the 
[2Fe-2S] cluster is passing electrons to the heme in Pa-BfrB. The magenta, green and black 
traces are the spectra recorded at 1 min, 3 min and 5 min of the reaction, respectively. The 
reoxidized [2Fe-2S] cluster peaks reach the maximum intensity at ~5min., suggesting the [2Fe-
2S] cluster has completed the process of passing out electrons.  Meanwhile, the Soret band 
shifts from 424 nm back to 418 nm, indicating the heme is being reoxidized.  The reoxidation of 
the heme indicates that the heme molecules pass out the electrons to the Fe3+ mineral in the 
BfrB central cavity. The reoxidation of the [2Fe-2S] is visualized more clearly in Figure 2-9C, 
in which a difference spectrum was obtained by subtracting a spectrum of Pa-BfrB at the same 
concentration as used in the experiment from the black trace (5 min) in Figure 2-9B. The full 
recovery of the [2Fe-2S] cluster peaks indicates that the reduced Bfd conducted a complete 
electron transfer to the heme. In addition, the iron being released during this process was 
monitored in a similar experiment, which was conducted in the presence of excess bipy. The 
time-dependent Fe2+ release was detected by the formation of [Fe(bipy)3]2+  at 523 nm. As 
expected, a fast iron release was observed and the maximum [Fe(bipy)3]2+ level was 24 µM , 
which is well correlated to the reduced Bfd concentration in the solution (Figure 2-9D) [8].  
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Figure 2-9 (A) UV-vis spectra of 30 µM oxidized Pa-Bfd (black) and reduced Pa-Bfd (red) 
upon addition of 0.8 equiv of sodium dithionite relative to oxidized Pa-Bfd [8].  (B) Spectral 
change upon addition of 0.08 µM iron loaded Pa-BfrB (590 iron/protein) to the reduced Pa-Bfd: 
(red) spectrum prior to addition of Pa-BfrB. (blue) 20s, (pink) 1min, (green) 3min and (black) 
5min after the addition of Pa-BfrB [8].  (C) Difference spectrum (red) obtained from subtracting 
a spectrum obtained from 0.08 µM Pa-BfrB from the black trace (5min)  in Figure (B). The 
resulted difference spectrum (red) is identical as the original oxidized Pa-Bfd at 30 µM (black) 
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[8]. (D) Time dependent formation of [Fe(bipy)3]
2+ 
 complex due to the release of the Fe
2+ 
during the reaction [8]. 
The Bfd Fold 
The Pa-Bfd fold was revealed for the first time as a part of the X-ray crystal structure of 
the Pa BfrB-Bfd complex [8]. As shown in Figure 2-10A and B, in the asymmetric unit, there 
are three BfrB subunit dimers. Well-defined electron density corresponding to Bfd molecules 
are observed at the interface of each BfrB subunit dimer, above each of the heme molecules. As 
shown in Figure 2-10C and D, the Bfd fold is a helix-turn-helix fold. Residues C4, C6, C38 and 
C41 located in loops 1 and 3 coordinate the [2Fe-2S] cluster. The distances of Fe-Fe, Fe-S (Cys) 
and Fe-S2- in the [2Fe-2S] cluster are similar to those observed in structures of [2Fe-2S] 
containing proteins. The average Fe-Fe distance is 2.85 Å, and the average Fe-S (Cys) and Fe-
S2- distances are 2.31 and 2.22 Å respectively. Loop 1 contains residues C4 and C6, followed by 
α-1, which is a 3-turn helix. Loop 2 follows α-1 helix and leads to a 2-turn helix α-2, the 
shortest helix in the structure. Loop 3 follows α-2 and contains residues C38 and C41. α-3, 
connected by L3, is the longest helix in the structure. α-3 has 4 turns and spans from residues 
C41 to C57, which is the last residue that has observable electron density. The missing electron 
density of the last six amino acids from C terminal of Bfd suggest the C terminal tail is 
disordered [8].  
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Figure 2-10 Pa-Bfd structure as a part of the Pa BfrB-Bfd complex (A) The asymmetric unit 
contains three BfrB subunit dimers, each of which associates with a Pa-Bfd molecule (cyan) [8]. 
(B) Fo-Fc omit map contoured at 3σ showing the electron density (magenta) of Bfd chain G [8]. 
(C) Helix-turn-helix structure of Pa-Bfd [8]. (D) The [2Fe-2S] cluster in Pa-Bfd is coordinated 
by C4 and C6 from L1, and C38 and C41 from L3 [8]. 
C-terminal truncated Bfd 
Despite significant effort made to crystallize Pa-Bfd alone, the best crystals we could 
obtain were needle clusters, which did not diffract well. The structure of Pa BfrB-Bfd complex 
showed that the electron density of the last 6 amino acids from Pa-Bfd C-terminal are missing, 
which suggests that the C-terminal tail in Bfd is disordered. Hence, we hypothesized that the 
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disordered C-terminal tail in Pa-Bfd contributes to the difficulties in crystallizing this molecule 
alone. Consequently, we truncated the Pa-Bfd after Leu56 in an effort to obtain the high-
resolution Pa-Bfd structure alone. We succeeded at growing crystals that diffracted to 1.25 Å, 
which were obtained from from Crystal Screen HT (Hampton Research) condition A1 (30% 
(v/v) 2-methyl-2,4-pentanediol, 100 mM sodium acetate pH 4.6, 20 mM CaCl2). The 
crystallographic data is shown in Table 2-1.  
Table 2-1 Crystallographic data of C-terminal truncated Bfd 
 Bfd 
Data Collection  
Unit-cell parameters (Å, o) a=23.93, b=49.68, c=39.87, β=96.9 
Space group P4212 
Resolution (Å)1 49.68-1.25 (1.27-2.25) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 86,612 
Unique reflections 25,583 
<I/σ(I)>1 10.0 (2.3) 
Completeness (%)1 99.6 (99.7) 
Multiplicity1 3.4 (3.2) 
Rmerge (%)1, 2 5.5 (50.4) 
Rmeas (%)1, 4 8.5 (71.8) 
Rpim (%)1, 4 4.5 (38.9) 
Refinement  
Resolution (Å) 30.96-1.25 
Reflections (working/test) 24,247/1,306 
Rfactor / Rfree (%)3 13.3/15.7 
No. of atoms (Bfd/Fe-
S/water) 
868/8/83 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.012 
Bond angles (o) 1.786 
Average B factor (Å2)  




Coordinate error, maximum 
likelihood (Å) 
0.12 
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Ramachandran Plot   
Most favored (%) 98.2 
Additionally allowed (%) 1.8 
 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for the 
ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
3) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in  the refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[10, 11].  Rpim = precision-
indicating (multiplicity-weighted) Rmerge[12, 13].  
In the asymmetric unit cell, there are two Bfd molecules (Figure 2-11A). Alignment of 
the truncated Bfd molecule with full-length Bfd molecule shows a perfect overlay of the two 
structures (Figure 2-11 B.).  
 
Figure 2-11 (A) In the asymmetric unit, there are two truncated Bfd molecules. (B) The 
truncated Bfd structure (pink) is identical to the full-length Bfd structure (cyan)      
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The Bfd fold is stabilized by phosphate 
(1) Phosphate is incorporated into the Bfd fold 
The three Bfd molecules in the asymmetric unit cell of the BfrB:Bfd complex are chain 
G, H and I respectively [8]. As shown in Figure 2-12 A, both chain I and chain G have crystal 
contacts with nearby complex molecules, while chain H is the only chain that does not 
experience crystal contacts. Therefore, compared to chain I and chain G, chain H is the chain 
that most closely represents solution conditions. The three Bfd chains are structurally similar, 
except that chain H has higher thermal factors and lacks electron density between residues 16 
and 33. As shown in Figure 2-12B, the average B factor of chain H is 64.0 Å, which is much 
higher than chain G and I (25.8 and 29.0 Å) [8].  
 
Figure 2-12 (A) In the asymmetric unit, BfrB (gray) binds Bfd (chain I, G and H). Bfd chain G 
and I experience crystal contacts (red) [8].  (B) Main chain average B-factors in Bfd chains G 
(magenta), I (orange) and H. The Cys ligands are highlighted by the vertical lines. The gap in 
the green trace (chain H) represents the missing electron density in chain H [8]. 
As shown in Figure 2-13A, the missing electron density in chain H (colored in gray), 
corresponds to the end of α-3, part of α-1, the whole of L2 and α-2, as well as a part of L3. In 
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contrast, in chain G, strong electron density corresponding to a phosphate ion is observed in this 
region (Figure 2-13B) [8]. The phosphate is coordinated by the side chains of R26, R29 and 
K46 and, via a crystal contact, by the side chain of K76 from a nearby BfrB molecule. Since 
R26, R29 and K46 are all positively charged, the phosphate ion is proposed to mediate 
otherwise repulsive interactions of these three residues [8]. Also, the phosphate enables the 
hydrophobic portions of these residues to pack against the Y25 side chain so that the  α-2 helix 
could be stabilized by the hydrophobic interactions [8]. The stabilization of  α-2 by phosphate 
maybe crucial for stabilizing the Bfd fold. This is because without the phosphate, the repulsive 
interactions from R26, R29 and K46 are likely to cause unfolding of the  α-2 helix. The 
instability of  α-2 could be transmitted by L3 and destabilize the [2Fe-2S] cluster. As mentioned 
earlier, the loss of [2Fe-2S] cluster would cause a further unfolding of the structure [8].  
 
Figure 2-13 (A) The missing electron density in chain H is represented by gray color. (B) 
Electron density modeled as a phosphate ion is observed in chain G. The phosphate ion is 
coordinated by R26, R29 and K46 in chain G, as well as K76 in a nearby BfrB molecule [8]. 
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(2) Removal of phosphate in solution causes loss of the [2Fe-2S] cluster 
Holo-Bfd dissolved in a buffer containing 50 mM potassium phosphate, 150 mM NaCl 
and 5 mM DTT was diluted 40 times into a buffer containing 150 mM Tris-Base, 250 mM NaCl 
and 3 mM TCEP. Therefore, the phosphate concentration in the buffer decreased to ~ 1.2 mM 
after the dilution. As shown in Figure 2-14A, upon decreasing the phosphate concentration, the 
characteristic [2Fe-2S] cluster peaks seen in the Pa-Bfd decrease dramatically within 3 h, 
leaving only the 280 nm peak and a shoulder at ~320 nm (black trace) in the UV-vis spectrum, 
observations that are indicative of loss the [2Fe-2S] cluster [8]. 
The CD spectra of Pa apo-Bfd in the phosphate buffer (black) and in Tris-Base buffer 
(red) are shown in Figure 2-14B. Compared to the Pa apo-Bfd in phosphate buffer 
([θ]222/ [θ]203 =  R∼ 0.45), the Pa apo-Bfd in Tris buffer shows lower [θ]222  and additional blue 
shift of the high-energy transition toward 201nm, with R~0.23. This indicates that the Pa apo-
Bfd loses α-helical structure upon removal of the phosphate, which supports the notion that the 
phosphate is important to stabilize the Bfd fold [8].  
 
Figure 2-14 (A) Bfd loses [2Fe-2S] cluster in the absence of phosphate [8]. (B) Bfd loses 
helical structure in the absence of phosphate [8]. 
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(3) Removal of the phosphate and the presence of Zn2+  accelerate the loss of the [2Fe-
2S] cluster 
As shown in Figure 2-15, upon diluting the Pa-Bfd stock into the buffer containing 150 
mM Tris-Base, 150 mM NaCl, 5 mM TCEP, 125 µM (ZnSO4.7H2O), pH 7.8, a rapid decrease 
of the [2Fe-2S] cluster characteristic peaks was observed within 5 min of the reaction (red 
trace). After 30 min of the reaction, the [2Fe-2S] cluster peaks have completely disappeared, 
only leaving an ill-defined shoulder ~ 320 nm (green). The resultant protein was dialyzed 
against 150 mM Tris-Base, 150 mM NaCl, 5 mM TCEP, 125 µM (ZnSO4.7H2O), pH 7.8 for 
3hrs. The UV-vis spectrum remains stable after the dialysis. Analysis of iron and protein 
concentration in the protein after dialysis shows a ratio of iron/protein of ~1.1. This suggest that 
disassembly of the [2Fe-2S] cluster in Bfd might result in the formation of a mononuclear iron 
center bound to Bfd. However, this hypothesis needs to be supported with additional 
experiments and spectroscopy. 
 
Figure 2-15 Pa-Bfd loses the [2Fe-2S] cluster in the buffer of 150 mM Tris-Base, 150 mM 
NaCl, 5 mM TCEP, 125 µM (ZnSO4.7H2O), pH 7.8. Black: Pa-Bfd in phosphate buffer. Red: 5 
min of the reaction. Green: 30 min of the reaction 
Wavelength (nm)
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(4) Truncated Bfd needs phosphate to stabilize the fold 
As describe above for full-length Bfd, structural and solution phase investigations were 
conducted to analyze the significance of phosphate binding to truncated Bfd. . As proposed 
above, in the full-length Bfd fold, R26, R29 and K46 interact with phosphate ion in solution to 
organize the structure delineated by L2-α-2-L3. Aligning the structure of truncated Bfd (pink) 
with that of full-length Pa-Bfd (cyan) molecule shows differences in the side chains of R26 and 
R29 (Figure 2-16A), which in the structure of the truncated Bfd form ionic interactions with a 
nearby molecule in the crystal (purple) through crystal contacts (Figure 2-16B).  In other words, 
under the particular crystallization condition, 0.5 µL solution of Bfd in 50 mM potassium 
phosphate, 150 mM NaCl, 5mM DTT, pH 7.0, mixed with 0.5 µL crystallization solution (30% 
(v/v) 2-methyl-2, 4-pentanediol, 100 mM sodium acetate pH 4.6, 20 mM CaCl2), the 
stabilization provided by phosphate in solution is replaced by contacts in the crystal. Hence, 
although phosphate is important to stabilize Bfd in solution, as the protein crystallizes, the role 
of phosphate can be replaced by interactions (crystal contacts) with other Bfd molecules in the 
crystal. However, when phosphate is removed in solution, the peaks characteristic of a [2Fe-2S] 
cluster in truncated Bfd decrease in intensity and disappear upon lowering the phosphate 
concentration. Hence, thse findings indicate that phosphate binding serves a structural role in 
the stabilization of holo-Bfd, full-length or truncated. 
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Figure 2-16 View of the “phosphate binding region” in truncated Bfd. (A) Overlay the structure 
of truncated Pa-Bfd (pink) and full-length Bfd (cyan) shows that the R26 and R29 in truncated 
structure have shifted compared to the full-length structure. (B) The “phosphate binding region” 
in the truncated Bfd is stabilized by a nearby molecule through crystal contacts. 
 
 
Figure 2-17 Removal of the phosphate from the truncated Bfd results loss of [2Fe-2S] cluster. 
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Overall Structure of the BfrB-Bfd complex 
The crystal structure of the BfrB-Bfd complex was determined at 2.0 Å resolution. The 
crystallographic data is shown in Table 2-2. As mentioned before, the asymmetric unit cell 
contains three BfrB subunit dimers, each associated with a Bfd molecule above the heme 
molecule. Hence, the 24-mer BfrB binds 12 Bfd molecules (Figure 2-18A). Alignment of the 
ferroxidase center in the complex and the ferroxidase center in BfrB alone show that they adopt 
identical conformations (Figure 2-18B). 
Table 2-2.  Crystallographic data for BfrB-Bfd refined to 2.0Å resolution. 
 BfrB-Bfd 
Data Collection  
Unit-cell parameters (Å, o) a=135.81, c=200.89 
Space group P4212 
Resolution (Å)1 200.89-2.00 (2.03-2.00) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 1,120,495 
Unique reflections 125,332 
<I/σ(I)>1 15.2 (3.0) 
Completeness (%)1 100 (100) 
Multiplicity1 8.9 (9.2) 
Rmerge (%)1, 2 11.7 (80.5) 
Rmeas (%)1, 4 13.3 (90.3) 
Rpim (%)1, 4 4.4 (29.6) 
Refinement  
Resolution (Å) 47.73-2.0 
Reflections (working/test) 118,964/6,294 
Rfactor / Rfree (%)3 15.2/18.3 
No. of atoms (BfrB/Bfd/Heme/Fe-
S/K+/Na+/phosphate/water) 
7,714/1,087/258/12/3/6/5/1,062 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.011 
Bond angles (o) 1.185 
Average B factor (Å2)  
All Atoms 24.0 
BfrB/Bfd 20.9/41.4 
Heme/Fe-S/ K+/Na+/phosphate 22.9/26.9/15.3/24.0/35.7 
Water 39.1 
Coordinate error, maximum 0.22 
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likelihood (Å) 
Ramachandran Plot   
Most favored (%) 99.3 
Additionally allowed (%) 0.7 
 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity 
measured for the ith reflection and <I(hkl)> is the average intensity of all reflections with 
indices hkl.  
3) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an  
identical manner using 5% of randomly selected reflections that were not included in  
the refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[2, 12].  Rpim = precision-
indicating (multiplicity-weighted) Rmerge[13, 14].  
 
 
Figure 2-18 (A) BfrB-Bfd complex structure (4E6K) shows that 12 Bfd molecules (cyan) bind 
to a 24-assembly BfrB molecule [8]. (B) Alignment of the ferreoxidase center of the free BfrB 
(pink) and Bfd in the complex (green) [8]. 
The Pa-BfrB−Bfd Interface 
At the BfrB-Bfd complex interface, a Bfd molecule binds between two BfrB subunits 
resulting in the burial of 607 Å2 at the interface of the complex [8]. The identities of residues 
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participating at the interface and their relative contribution to the buried surface are shown in 
Figure 2-19. The contribution of Bfd residues and BfrB residues to the total buried surface are 
plotted in Figure 2-19A and B respectively. The (*) and (:) on top of each bar respectively 
indicate that a particular residue is conserved or conservatively replaced in the amino acid 
sequence alignments of several BfrB and Bfd sequences from a number of pathogens (Table 2-
3A and B). The conservation of the interacting residues at the interface suggest that the Pa 
BfrB-Bfd interaction is biologically relevant and support the notion that the Pa BfrB-Bfd 
interaction is a wide spread mechanism for regulating cytosolic iron level in various Gram 
negative bacteria [8].  
 
Figure 2-19 Per-residue plot of surface area buried at the complex interface contributed from 
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Table 2-3A Sequence alignment of Pa-Bfd with Bfd-like molecules from different bacterial 
species. Conserved cysteine residues coordinating iron in the [2Fe-2S] cluster are highlighted 
by an arrow (↓) and residues buried at the Pa-BfrB-Bfd interface are denoted by (^).  Conserved 
residues across the alignment are in red, conservative substitutions in green and semi-
conservative substitutions in blue, sequence numbering according to Pa-Bfd [8] 
 
                                       1        10       20          30        40        50  
                                       |        |         |          |         |         |                                                 
Pseudomonas aeruginosa PAO1       -----MYVCLCQGVTDNQIRDAIYEGCCS-YREVREATGVGTQCGKCACLAKQVVRETL- 
Escherichia coli O157             -----MYVCLCNGVSDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Escherichia coli K12              -----MYVCLCNGISDKKIRQAVRQFSPHSFQQLKKFIPVGNQCGKCVRAAREVMEDEL- 
Salmonella typhimurium            -----MYVCLCNGISDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Salmonella enterica serovar Typhi -----MYVCLCNGISDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Salmonella enterica choleraesuis  -----MYVCLCNGISDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Klebsiella pneumoniae             -----MYVCLCNGVSDKKIRQVVRQFQPQSFQQLRKFVPVGNQCGKCVRAAREVMEDEL- 
Yersinia pestis                   -----MYVCLCNAVSDKVIRKAVRQHQPHTVKQLRQLVPIGSDCGKCIRQAREILIEEL- 
Yersinia pseudotuberculosis       -----MYVCLCNAVSDKVIRKAVRQHQPHTVKQLRQLVPIGSDCGKCIRQAREILIEEL- 
Yersinia enterocolitica           -----MYVCLCNAVSDKVIRNAVRQHHPHTIQQLRQLVPIGTDCGKCIRQAREILIEER- 
Aeromonas salmonicida             -----MYVCLCRGITDTQIRKAVQAGKSE-FRQLKQSLEVGAQCGKCVRMTMEIIAAELD 
Vibrio cholerae El                -----MYVCLCHGVSDKKIRRLVAEQGITDIKGIKRCTALGSQCGKCVRQAKEIIEESL- 
Vibrio cholerae 0395              -----MYVCLCHGVSDKKIRRLVAEQGITDIKGIKRCTALGSQCGKCVRQAKEIIEESL- 
Vibrio vulnificus                 -MSCNMYVCLCHGVSDKKIRKLVIEQGVADIRGIKKCTALGSQCGKCIRMAKEIINETA- 
Shigella flexneri 2a 2457T        -----MYVCLCNGVSDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Shigella flexneri 2a str301       -----MYVCLCNGVSDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Shigella dysenteriae              -----MYVCLCNGVSDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCIRAAREVMQDEL- 
Erwinia carotovora                -----MYVCLCNAISDKAIRNAVRQHQPQSMQQLRKLVPIGTDCGKCIRQARVIFEEEQ- 
Enterobacter cloacae              -----MYVCLCNGVSDTKIRQAVRQFQPQSFQQLRKFVPVGNQCGKCVRAAREIMQDEL- 
Serratia sp.                      -----MYVCLCNAVTDKAIRKAVRQHNPHTMKQLRELVPIGTDCGKCIRQARQIMVEES- 
Citrobacter koseri                -----MYVCLCNGVSDKKIRQAVRQFHPQSFQQLRKFIPVGNQCGKCVRAAREVMQDEL- 
Acinetobacter sp.                 MRMTLMYVCLCRGITDQDIKDAVASGAES-YREVRERLDLGTCCGRCAPEAKSIINEEL- 
                                       ^^^ ^^ ^ ^^^                         ^^ ^^ ^^             
 
                                            60        70 
                                            |         | 
Pseudomonas aeruginosa PAO1       ----NDLQSAQPVPAFGTTAFVAA 
Escherichia coli O157             ----MQMPEFKEIA---------- 
Escherichia coli K12              ----MQLPEFKESA---------- 
Salmonella typhimurium            ----TQMPEFKEIA---------- 
Salmonella enterica serovar Typhi ----TQMPEFKEIA---------- 
Salmonella enterica choleraesuis  ----TQMPEFKEIA---------- 
Klebsiella pneumoniae             ----TTMPEFKEIA---------- 
Yersinia pestis                   ----ANIPEMNDVA---------- 
Yersinia pseudotuberculosis       ----ANIPEMNDVA---------- 
Yersinia enterocolitica           ----ANIPEMNDVA---------- 
Aeromonas salmonicida             KAELETAPLYYEVA---------- 
Vibrio cholerae El                ------IAQFKLAS---------- 
Vibrio cholerae 0395              ------IAQFKLAS---------- 
Vibrio vulnificus                 ------PALFKQAS---------- 
Shigella flexneri 2a 2457T        ----MQMPEFKEIA---------- 
Shigella flexneri 2a str301       ----MQMPEFKEIA---------- 
Shigella dysenteriae              ----MQMPEFKEIA---------- 
Erwinia carotovora                ----AKIPDMYKVA---------- 
Enterobacter cloacae              ----MQIPEYKEIA---------- 
Serratia sp.                      ----GTIIPMHEVA---------- 
Citrobacter koseri                ----MQMPEFKEIA---------- 
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Table 2-3B Sequence alignment of Pa-BfrB and Bfr from different bacterial species.  Residues 
buried at the Pa-BfrB-Bfd interface are denoted by (^).  Conserved residues across the 
alignment are in red, conservative substitutions in green and semi-conservative substitutions in 
blue [8]. 
                                             10        20        30        40        50        60 
                                              |         |         |         |         |         | 
Pseudomonas aeruginosa PAO1          MKGDKKVIQHLNKILGNELIAINQYFLHSRMWNDWGLKRLGAHEYHESIDEMKHADKLIE 
Escherichia coli O157                MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLMRLNDVEYHESIDEMKHADKYIE 
Escherichia coli K12                 MKGDTKVINYLNKLLGNELVAINQYFLHARMFKNWGLKRLNDVEYHESIDEMKHADRYIE 
Salmonella typhimurium               MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLTRLNDVEYHESIDEMKHADKYIE 
Salmonella enterica serovar Typhi    MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLTRLNDVEYHESIDEMKHADKYIE 
Salmonella enterica choleraesuis     MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLTRLNDVEYHESIDEMKHADKYIE 
Klebsiella pneumoniae                MKGDVKIISYLNKLLGNELVAINQYFLHARMFKNWGLMRLNDIEYHESIDEMKHADKYIE 
Yersinia pestis                      MKGDKKIIAHLNKLLGNELVAINQYFLHARMFKNWGLMRLNDKEYHESIDEMKHADKYIE 
Yersinia pseudotuberculosis          MKGDKKIIAHLNKLLGNELVAINQYFLHARMFKNWGLMRLNDKEYHESIDEMKHADKYIE 
Yersinia enterocolitica              MKGDKKIIAHLNKLLGNELVAINQYFLHARMFKNWGLMRLNDKEYHESIDEMKHADKYIE 
Aeromonas salmonicida                MKGDPKIIAHLNKVLANELIAINQYFLHARIYDDWGLKALGHKEYHESIDEMKHADELVK 
Vibrio cholerae El                   MKGDPVIIQHLNKVLANELIAINQYFLHARMYKDWGLKHLADKEYHESIDEMKHADHIVE 
Vibrio cholerae 0395                 MKGDPVIIQHLNKVLANELIAINQYFLHARMYKDWGLKHLADKEYHESIDEMKHADHIVE 
Vibrio vulnificus                    MKGDPIIIQHLNKVLGNELIAINQYFLHARMYKDWGLKHLADKEYHESIDEMKHADHLVE 
Shigella flexneri 2a 2457T           MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLMRLNDVEYHESIDEMKHADKYIE 
Shigella flexneri 2a str301          MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLMRLNDVEYHESIDEMKHADKYIE 
Shigella dysenteriae                 MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLMRLNDVEYHESIDEMKHADKYIE 
Erwinia carotovora                   MKGDKKVITHLNKLLGNELVAINQYFLHARMFKNWGLTRLNDHEYHESIDEMKHADRYIE 
Enterobacter cloacae                 MKGDVKIISYLNKLLGNELVAINQYFLHARMFKNWGLMRLNDVEYHESIDEMKHADKYIE 
Serratia sp.                         MKGDKKIIAHLNKLLGNELVAINQYFLHARMFKNWGLMRLNDKEYHESIDEMKHADRYIE 
Citrobacter koseri                   MKGDVKIINYLNKLLGNELVAINQYFLHARMFKNWGLTRLNDVEYHESIDEMKHADKYIE 
Acinetobacter sp.                    MKGNRDVINQLNQVLYHHLTAINQYFLHSRMFNDWGIEKLGSSEYKESIRQMKHADKIIE 
                                                ^              ^   ^                                                                 
                                             70        80        90       100       110       120 
                                              |         |         |         |         |         | 
Pseudomonas aeruginosa PAO1          RILFLEGLPNLQDLGKLLIGENTQEMLQCDLNLELKATKDLREAIVHCEQVHDYVSRDLL 
Escherichia coli O157                RILFLEGIPNLQDLGKLGIGEDVEEMLQSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Escherichia coli K12                 RILFLEGLPNLQDLGKLNIGEDVEEMLRSDLALELDGAKNLREAIGYADSVHDYVSRDMM 
Salmonella typhimurium               RILFLEGIPNLQDLGKLGIGEDVEEMLRSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Salmonella enterica serovar Typhi    RILFLEGIPNLQDLGKLGIGEDVEEMLRSDLRLELEGAKDLREAIAYADNVHDYVSRDMM 
Salmonella enterica choleraesuis     RILFLEGIPNLQDLGKLGIGEDVEEMLRSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Klebsiella pneumoniae                RILFLEGIPNLQDLGKLGIGEDVEEMLRSDLRLELEGAQNLREAIAYADSVHDYVSRDMM 
Yersinia pestis                      RILFLEGIPNLQELGKLNIGEDVEEMLKSDLALELSGATDLREGIAYADSIHDYVSRDLL 
Yersinia pseudotuberculosis          RILFLEGIPNLQELGKLNIGEDVEEMLKSDLALELSGAIDLREGIAYADSIHDYVSRDLL 
Yersinia enterocolitica              RILFLEGIPNLQDLGKLNIGEDVEEILKSDLALELAGAKDLREGIAYADSIHDYVSRDLL 
Aeromonas salmonicida                RVLFLEGLPNLQDLGKLRIGETVEEMLRCDLSLEMDAIPDLKVAIAYAESVQDYISRDLF 
Vibrio cholerae El                   RILFLEGIPNLQDLGKLMIGEDVQEMLECDLKLELIAIPDLKEAIAYAEKVRDYVSRDLF 
Vibrio cholerae 0395                 RILFLEGIPNLQDLGKLMIGEDVQEMLECDLKLELIAIPDLKEAIAYAEKVRDYVSRDLF 
Vibrio vulnificus                    RILFLEGIPNLQDLGKLMIGEDTQEMLECDLKLEMAAIPDLKAAIAYAEDVHDYVSRDLF 
Shigella flexneri 2a 2457T           RILFLEGIPNLQDLGKLGIGEDVEEMLQSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Shigella flexneri 2a str301          RILFLEGIPNLQDLGKLGIGEDVEEMLQSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Shigella dysenteriae                 RILFLEGVPNLQDLGKLGIGEDVEEMLQSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Erwinia carotovora                   RILFLEGIPNLQDLGKLNIGEDVEEVLRSDLQLELDGAKNLREAIAYSDSVHDYVSRDLM 
Enterobacter cloacae                 RILFLEGIPNLQDLGKLGIGEDVEEMLRSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Serratia sp.                         RILFLEGLPNLQDLGKLNIGEDIEEILRSDLALELDGAKNLREAIAYADSIHDYVSRDLM 
Citrobacter koseri                   RILFLEGIPNLQDLGKLGIGEDVEEMLQSDLRLELEGAKDLREAIAYADSVHDYVSRDMM 
Acinetobacter sp.                    RILFLEGLPNLQHLGKLYIGQHTQEVLNCDVRKVKENIETLKKAVEISEIQQDYVSRDLV 
                                            ^^^^^^^^^^^^^^   ^   ^    
                                            130       140       150 
                                              |         |         | 
Pseudomonas aeruginosa PAO1          KDILESEEEHIDYLETQLGLIQKVGLENYLQSHMHEDD- 
Escherichia coli O157                IEILADEEGHIDWLETELDLIGKIGLQNYLQSQIKV-ND 
Escherichia coli K12                 IEILRDEEGHIDWLETELDLIQKMGLQNYLQAQIRE-EG 
Salmonella typhimurium               IEILADEEGHIDWLETELDLIAKLGMQNYLQSQIKV-TD 
Salmonella enterica serovar Typhi    IEILADEEGHIDWLETELDLIAKLGMQNYLQSQIKV-TD 
Salmonella enterica choleraesuis     IEILADEEGHIDRLETELDLIAKLGMQNYLQSQIKV-TD 
Klebsiella pneumoniae                IEILADEEGHIDWLETELDLIGKIGLQNYLQSQIKV-SD 
Yersinia pestis                      KEILVDEEEHIDWLETELSLIDRLGIQSYSQAQLA--KD 
Yersinia pseudotuberculosis          KKILVDEEEHIDWLETELSLIDRLGIQSYSQAQLA--KD 
Yersinia enterocolitica              KEILADEEGHIDWLETELSLIERLGIQNYSQAQLA--KD 
Aeromonas salmonicida                QDILEDEEEHVDWLETQLDLIDRIGLENYQQSQLHHGSS 
Vibrio cholerae El                   QEILEDEEEHVDWLETQLGLIDMTGIQNYLQAQFVDDE- 
Vibrio cholerae 0395                 QEILEDEEEHVDWLETQLGLIDMTGIQNYLQAQFVDDE- 
Vibrio vulnificus                    QDILEDEEEHVDWLETQLGLIQLTGIENYLQAQFVDED- 
Shigella flexneri 2a 2457T           IEILADEEGHIDWLETELDLIGKIGLQNYLQSQIKV-KD 
Shigella flexneri 2a str301          IEILADEEGHIDWLETELDLIGKIGLQNYLQSQIKV-KD 
Shigella dysenteriae                 IEILADEEGHIDWLETELDLIGKIGLQNYLQSQIKV-KD 
Erwinia carotovora                   IEILADEEGHIDWLETELDLIARLGIQNYLQAQLK--AE 
Enterobacter cloacae                 IQILADEEGHIDWLETELDLIGKIGLQNYLQSQIKV-ED 
Serratia sp.                         IEILADEEGHIDWLETELDLIARLGIQNYAQAQILERKD 
Citrobacter koseri                   IEILTDEEGHIDWLETELDLIAKIGLQNYLQSQIKV-DD 
Acinetobacter sp.                    QEILEKEEEYWDWTTTQLDLIESIGIENYIQSQV----- 
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A zoomed-in view of the Pa BfrB-Bfd interface is shown in Figure 2-20.  Pa-Bfd (cyan) 
is bound at the interface of Pa-BfrB subunit A (green), and subunit B (gray). Y2, L5, K40 and 
M1 are the four residues with the largest contributions to the buried Pa Bfd surface: (1) Bfd Y2 
is held by a binding cleft on BfrB surface formed by E and L, (2) Bfd L5 buries in a pocket 
on  the BfrB surface formed by BfrB L, P-, N/0, L/, Q/, L// and I/-,(3) Bfd K40 interacts 
hydrophobically with BfrB K/ and forms hydrogen bonds with carbonyl oxygen of BfrB Q/ 
and L/4, and (4) the Bfd amine group of M1 forms hydrogen bonds with carboxyl side chains of 
E and E on BfrB and interacts hydrophobically with BfrB L// L/, I/-, G0 and C-. 
 
Figure 2-20 BfrB-Bfd interface showing the Bfd residues in cyan and BfrB subunit A and B in 
green and gray, respectively. The oxygen and nitrogen atoms are shown as red and blue, 
respectively. The H-bonding interactions are labeled with dotted lines. 
Bfd [2Fe-2S] cluster electron transfer pathway to the BfrB heme  
From the functional studies discussed above, we concluded the role of the [2Fe-2S] 
cluster is to transfer electrons to the heme in Pa-BfrB. The structure of the Pa BfrB−Bfd 
complex reveals that the edge-to-edge distance between the [2Fe-2S] cluster in Pa-Bfd and 
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heme in Pa-BfrB is 15.1 Å [8]. Using the coordinates of the Pa Bfr-Bfd complex, the most 
probable path for electron transfer from the [2Fe-2S] cluster to the heme was calculated with the 
aid of the program Harlem. The electron is likely to proceed from S2 in the iron sulfur cluster of 
Pa-Bfd to a heme vinyl β carbon (CBB) in Pa-BfrB, via conserved residues Q72 and L71 in 
subunit B (Figure 2-21) [8].  
 
Figure 2-21 Best electron transfer path from [2Fe-2S] cluster to heme calculated by the 
program Harlem [8]. 
 Taken together, the results from the in vitro functional studies, the structure of the 
BfrB-Bfd complex, and the calculation of the electron transfer path  allow us to summarize the 
process of electron transfer from the Bfd to the core Fe3+ in Figure 2-22, where the [2Fe-2S] 
cluster mediates electrons to heme, and the heme further passes the electrons to the BfrB Fe3+ 
core to reduce and mobilize the stored irons.  
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Figure 2-22 [2Fe-2S] cluster transfers electron via heme to the core Fe3+ to mobilize Fe2+ 
 
Discussion 
Bfd fold is a versatile metal binding motif  
As mentioned above, sequence alignments of Pa Bfd and Bfd in different bacteria show 
that in Bfd four conserved cysteines are arranged in a unique C-X1-C-X31-32-C-X2 motif, which 
is distinct from the C-X5-C-X2-C-X37-C arrangement in classical ferredoxins [6].  Bfds are ~50 
residues shorter than [2Fe-2S] ferredoxins from bacteria, plants, fungi, and vertebrates [6]. The 
helix-turn–helix fold of Bfd is also distinct from the classical [2Fe-2S] ferredoxins, which 
usually incorporates a β sheet. Although the [2Fe-2S] cluster in Pa-Bfd has been shown to 
function as electron carrier in Pa-BfrB iron mobilization process, yet there might be other 
functions of Bfd that haven’t been explored. For example, the possibility that the Bfd also 
functions as a scaffold for [2Fe-2S] cluster assembly has not been excluded. Therefore, we 
conclude that Bfd is a class of [2Fe-2S] ferredoxin distinct from the classical ferredoxins.  
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Using the Bfd sequence to search database [8, 14] shows that the Bfd sequence matches 
a large, manually curated Pfam fimily, Fer2_BFD (PF04324). This family contains single and 
multiple domain proteins where the C-X1-C arrangement is highly conserved and the C-X2-C 
arrangement is partially conserved. The Fer2_Bfd sequence has been found in a variety of 
multidomain enzymes, such as nitrate, nitrite, and sulfite reductases, FAD-dependent 
oxidoreductases, nitrogen fixation (NifU) proteins, and copper and mercury transport proteins. 
Searching and aligning the Bfd structure using I-COFACTOR [15], DALI [16] and 
PdBeFold[17] strongly suggest that the Bfd fold has been observed for the first time in a single 
domain protein. However, the Bfd fold matches closely to certain portions of several 
multidomain proteins. For example, heterooctameric proline dehydrogenase (PDH1) from 
Pirococcus Horikoshii does not have significant sequence similarity to Bfd, however, a small 
portion of its α-subunit (magenta) is found to contain an equivalent of the Bfd fold (cyan) 
(Figure 2-23A) [8]. Chaperone CopZ from Archaeoglobus fulgidus is a two-domain protein that 
binds a Zn2+ and a [2Fe-2S] cluster in its N-terminal domain. It is a member of the Fer2_BFD 
family, who shares 60% sequence similarity with Pa-Bfd in the stretch flanking the C-X1-C 
motif. As shown in Figure 2-23B, in CopZ-NT, the [2Fe-2S] cluster is coordinated by C75, 
C77, C109 and C119.  The C75 an C77 in  CopZ are structurally equivalent to the C4 and C6 in 
Bfd. A subsequent α-helix in CopZ-NT (magenta) is also aligned with the α-1 helix in Pa-Bfd 
(cyan). C119 in CopZ is structurally equivalent to C41 in Pa-Bfd. In contrast, C109 is on a on a 
one-turn α-helix (green) in CopZ-NT and therefore is structurally distinct from C38 in Pa-Bfd 
L3. Taken together, the structural and sequence alignments above show that Bfd fold is a 
versatile metal-binding structural motif that has been incorporated into larger proteins with 
various functions, both from the Fer2_BFD family and non Fer2_BFD family [8]. 
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Figure 2-23 (A) Structural alignment of Pa-Bfd (cyan) with PDH1 (PDB:1Y56) shows that Bfd 
matches a proportion of the a-subunit of PDH1 (magenta) [8]. (B) Structural alignment of Bfd 
with a portion of the N’-terminal domain of CopZ-NT (PDB:2HU9) [8] 
Phosphate is important for stabilizing the Bfd fold  
From the structural analysis as well as UV-vis and CD spectral analysis above, 
phosphate is important to stabilize the Bfd fold. In addition, this idea was also proved by 
comparing the structural fluctuations in the phosphate-bound Pa-Bfd and phosphate –free Pa-
Bfd structures in silico using a coarse-grained normal-mode analysis [8]. As shown in Figure 2-
24, the calculation suggest that in the phosphate bound structure (Figure 2-24A), the residue 
G21, C38, C39 and K40 have larger fluctuations than other residues. Removal of phosphate 
causes a relatively large increase in the fluctuations of Y25, R26, and R29 in α-2 and A42 and 
K46 in α-3 (Figure 2-24B)[8]. This is consistent with the structural analysis that the binding of 
the phosphate stabilizes these residues on α-2 and α-3 helices. In addition, this conclusion is 
also supported by the facts that (1) the recombinant Pa-Bfd can only be purified in a phosphate 
buffer. (2) The preparation and isolation of apo-Bfd can only be achieved with the high 
concentration of phosphate. (3) The Pa BfrB-Bfd complex can only be obtained if both proteins 
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are dissolved in phosphate buffer and if the crystallization solution contains high phosphate 
concentrations [8]. 
Taken together, the results from crystallography biochemical experiments in solution 
and experiments in silico allow us to conclude that in solution Bfd experiences an equilibrium 
between a folded α-helical structure and a partially disordered structure, which is regulated by 
the binding of the phosphate ion. Since the repulsive interactions from R26, R29 and K46 
contribute to the instability of the α-2 helix, we propose that mutating one of the R26 or R29 
residues to a negatively charged residue, for example, Glu, may stabilize this region so that the 
Bfd fold may be stabilized without the need of phosphate. However, more experiments need to 
be carried out to support this idea.  
 
Figure 2-24 In silico prediction shows the phosphate stabilizes the Pa-Bfd fold. (A) Plot of per 
residue mobility in the phosphate-bound Bfd structure [8]. (B) Plot of the relative change of the 
mean square fluctuation of Bfd residues upon removing the phosphate from the Bfd structure 
[8]. 
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CHAPTER III 
Identifying the Hot Spot for the Interaction between Bacterioferritin 
(BfrB) and Its Associated Ferredoxin (Bfd) 
Introduction 
Iron is essential for bacteria due its involvement in multiple metabolic processes 
including respiration (heme-containing cytochromes, [Fe-S]-containing ferredoxins) and key 
enzymatic reactions ([Fe-S]-containing proteins, such as fumarase and aconitase of the TCA 
cycle) [1]. Pathogenic bacteria must obtain iron from the host to support growth, but humans 
maintain extremely low concentrations of free iron, which are further reduced during infections 
[2, 3]. In bacterial cells iron homeostasis plays a pivotal role in guarding against iron-induced 
toxicity caused by the propensity of free iron to stimulate the formation of reactive oxygen 
species (ROS) such as superoxide, hydrogen peroxide and the highly destructive hydroxyl 
radical [4]. Consequently, free levels of iron in bacteria are tightly regulated to insure 
sufficiency for metabolic needs, while preventing iron-induced toxicity [5]. In humans, iron is 
stored in ferritin (Ftn) [6],  while in bacteria iron reserves are stored in Ftn and in 
bacterioferritin (Bfr), of which the latter is present only in bacteria [7, 8]. Ftns, bacterial Ftns 
and Bfrs assemble from 24 subunits into a spherical and hollow structure with an outer diameter 
of 120 Å and an inner diameter of 80 Å, where ≈3,500 iron atoms can be stored in the form of 
an Fe3+ mineral. Despite the superficial structural similarity between eukaryotic and prokaryotic 
Ftns and Bfrs, the small amino acid sequence homology (<18%) strongly influences the packing 
of the 24-mer protein shell, as well as its function [9, 10].  
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Bfrs are unique in possessing intrinsic heme groups, which are bound at 2-fold 
intersubunit sites by axial coordination of the heme-iron by methionine residues from adjacent 
subunits (Figure 3-1A). Hence, a 24-mer Bfr can be thought as being assembled from 12 
subunit dimers, each harboring a heme, which is buried deep below the protein surface (≈13 Å), 
such that the heme propionates reach into the interior cavity (Figure 3-1B) [7]. Bfrs function by: 
(i) utilizing O2 or H2O2 to oxidize Fe2+ and store Fe3+ in their internal cavity (core), and (ii) 
accepting electrons to reduce Fe3+ in their core and mobilize Fe2+ to the cytosol [11, 12] In 
bacteria, the free iron concentration (Fe2+) required for Fur regulation is maintained by a 
dynamic equilibrium between Fe3+ stored in ferritin-like molecules and free, available Fe2+. 
Hence, one function of ferritin-like molecules is to maintain the cytosolic Fe2+ concentrations 
that enable Fur, the major iron-responsive regulator which is conserved in many bacteria [13], 
to perform its broad range of regulatory functions that link iron homeostasis to broader bacterial 
metabolism [14-16]. For example, Bfr mutants of Mycobacterium tuberculosis suffer from iron-
mediated oxidative stress and are unable to persist in mice and guinea pig models of infection 
[17, 18]. A Bfr-deficient mutant of Nisseria gonorrhoeae is growth impaired in iron-limited 
medium and more sensitive to killing by hydrogen peroxide [19], and in the plant pathogen 
Erwinia chrysanthemi, mutation of the bfr gene results in impaired iron utilization and growth 
defects [20]. 
Early studies with Escherichia coli suggested that mobilization of iron from Bfr requires 
interactions with a ferredoxin, dubbed Bfd (bacterioferritin-associated ferredoxin) because the 
bfd gene is adjacent to the bfr gene [21-23]. Mining the global genetic response of P. 
aeruginosa to high and low iron conditions [24], we noticed that of the ≈120 genes reported to 
be up-regulated by low-iron conditions, the expression of bfd is up-regulated 200 fold and that 
of a gene coding for a ferredoxin reductase (fpr) is increased 3-fold[24]. In contrast, the bfrB 
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gene is down-regulated under iron limiting conditions [25]. The strong up-regulation of the bfd 
gene in response to low iron led us to hypothesize that the Bfd protein functions in the 
mobilization of iron stored in BfrB, by accepting electrons from the ferredoxin reductase (FPR) 
and transferring these to the ferric iron in BfrB for subsequent mobilization of Fe2+ (Figure 3-
1B) [26]. We cloned the genes, characterized the BfrB, Bfd, and FPR proteins biochemically 
and structurally [27, 28], and showed that Bfd, FPR and NADPH are sufficient to mobilize iron 
from BfrB in vitro (Figure 3-1C) [26].  
 
Figure 3-1 Structural organization of BfrB (PDB 3IS8) and its iron mobilization model. (A) 
View of subunit dimer harboring a heme molecule (red), which is coordinated by a conserved 
methionine in each of the subunits. (B) Inside view of the BfrB interior cavity where iron 
mineral is stored. Heme (red) is buried below the protein shell surface with the heme 
propionates extending into the cavity. (C) Proposed model of iron mobilization from BfrB 
central cavity, which is promoted by Bfd mediated electron transfer across the protein shell to 
reduce the Fe 3+ mineral to Fe2+. 
More recently, we solved the X-ray crystal structure of the BfrB-Bfd complex [12]. The 
asymmetric unit cell contains three BfB subunit dimers, each associated with a Bfd molecule 
(Figure 3-2A), so that the biological assembly is a nearly spherical 24-mer BfrB with 12 Bfd 
molecules (Figure 3-2B). Each Bfd binds at an identical site on BfrB, at the interface of a 
subunit dimer, above each of the heme molecules, placing the [2Fe-2S] cluster of Bfd 15.1 Å 
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from the heme-iron in BfrB, which is buried within each subunit dimer (Figure 3-2A). Studies 
in solution demonstrated that formation of the BfrB-Bfd complex enables the heme in BfrB to 
conduct electrons from the [2Fe-2S] cluster in Bfd to the mineral core, thus accelerating 
reduction of the Fe3+ mineral core and mobilization of Fe2+ [12, 26]. A zoomed-in view of one 
of the 12 identical Bfd-binding sites on BfrB (Figure 3-2C) illustrates the proximity of the [2Fe-
2S] cluster to the BfrB surface and shows the interactions that are likely important to stabilize 
the complex: (i) The side chain of Y2 in Bfd buries in a cleft on the BfrB surface, which is 
formed by the side chains of E81 in subunit A (E) and L68 in subunit B (L), (ii) the side 
chain of L5 in Bfd buries in a pocket formed mostly by L, N/0, L/, and L//, (iii) the backbone 
NH group of M1 forms H-bonds with carboxyl side chains in E and E on BfrB and its side 
chain interacts hydrophobically with L// L/, I/-, G0 and C- on the BfrB surface, and (iv) the 
side chain of K40 in Bfd interacts hydrophobically with the side chain of K/ in BfrB and forms 
hydrogen bonds with carbonyl oxygen of BfrB Q/ and L/4. 
In this study we examined the BfrB-Bfd interaction in solution with the aid of surface 
plasmon resonance (SPR) and isothermal titration calorimetry (ITC) and determined that the 12 
Bfd-binding sites on BfrB, which are structurally identical, are also equivalent and independent. 
Bfd binds at each of the sites on BfrB with Kd of approximately 3 μM, and the interaction, 
although endothermic, is favored by a relatively large change in entropy. Having obtained a 
benchmark for the interaction between the two proteins, we mutated several residues 
participating at the interface to alanine. These experiments allowed us to understand how the 
different side chains contribute to the stability of the complex, and to determine that the cleft 
and pocket on BfrB where the side chains of Y2 and L5 bury to anchor Bfd are essential to the 
stability of the BfrB complex and to the Bfd-promoted mobilization of core iron from BfrB.  
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Figure 3-2 Structure of the BfrB-Bfd complex (PDB:4E6K). (A) View of a Bfd molecule 
(cyan) binding at the interface of a BfrB subunit dimer above the harbored heme molecule (red). 
(B) A 24-assembly BfrB binds 12 Bfd molecules. (C) View of the BfrB-Bfd interface. Bfd side 
chains (cyan) bury into binding clefts on the BfrB surface as well as form ionic interactions 
(dotted lines) with BfrB surface residues; BfrB subunit A and B are shown in green and gray 




Mutations were introduced to the recombinant bfrB (L68A, E81A, E85A, L68A/E81A) 
and bfd (L5A, Y2F, Y2A, K40A) genes with the aid of the Quick Change mutagenesis kit 
(Stratagene, La Jolla, CA) using manufacturer instructions. Primer pair sequences are provided 
in Supporting Information. Mutations were confirmed by sequencing (ACGT Inc. Wheeling, 
IL). Plasmids carrying the desired mutations were transformed into E. coli Arctic express (DE3) 
RIL competent cells (Agilent Technologies, Santa Clara, CA).  
Below listed the information of the primers for the mutations: 
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L68A: Forward: 5' CGTATTCTGTTTCTGGAAGGTGCGCCGAATCTGCAGGATCTGGG 3' 
           Reverse: 5' CCCAGATCCTGCAGATTCGGCGCACCTTCCAGAAACAGAATACG 3' 
E81A: Forward: 5' GGGCAAACTGCTGATTGGTGCGAACACCCAGGAAATGCTGCAG 3' 
            Reverse: 5' CTGCAGCATTTCCTGGGTGTTCGCACCAATCAGCAGTTTGCCC 3' 
E85A: Forward: 5 'GGTGAAAACACCCAGGCGATGCTGCAGTGCGATC 3' 
            Reverse:  5' GATCGCACTGCAGCATCGCCTGGGTGTTTTCACC 3' 
Y2A: Forward: 5' GAAGGAGATATACATATGGCGGTGTGCCTGTGCCAGGG 3' 
          Reverse: 5' CCCTGGCACAGGCACACCGCCATATGTATATCTCCTTC 3' 
Y2F: Forward: 5' GGAGATATACATATGTTTGTGTGCCTGTGCCAGG 3' 
          Reverse: 5' CCTGGCACAGGCACACAAACATATGTATATCTCC 3' 
L5A: Forward: 5' CATATGTATGTGTGCGCGTGCCAGGGTGTGAC 3' 
           Reverse: 5' GTCACACCCTGGCACGCGCACACATACATATG 3’ 
K40A: Forward: 5' GCACCCAGTGCGGCGCGTGCGCAAGCCTGG 3' 
             Reverse: 5' CCAGGCTTGCGCACGCGCCGCACTGGGTGC 3' 
Protein Expression and Purification.  
Recombinant BfrB (wild type and mutants) was expressed and purified using a 
previously reported protocol [29] with the following modifications:  E. coli Arctic express RIL 
cells harboring the recombinant pET11a/bfrB construct were cultured overnight at 37 °C in 50 
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mL LB medium containing 100 µg/mL ampicillin and 20 µg/mL gentamicin. The cells were 
then cultured in 1L of fresh LB containing no antibiotics for 3 h at 30 °C, transferred to a shaker 
incubator pre- equilibrated at 10 °C and incubated for 45 min before protein expression was 
induced by addition of 1 mM 1-thio-D-galactopyranoside (IPTG). Cells were cultured for an 
additional 48 h at 10 °C before they were harvested by centrifugation and stored at -20 °C. To 
lyse the cells cell paste was suspended in a solution containing 50 mM Tris-Base (pH 7.6), 5 
mM dithiothreitol (DTT), 0.5 mM phenylmethanesulfonylfluoride (PMSF) and 0.5% TritonTM 
X-100 (Sigma) and sonicated on ice. Cell debris were pelleted by centrifugation at 4 °C and 
19,500 rpm and the supernatant was dialyzed against 50 mM Tris-Base (pH 7.6), then loaded 
onto a Q-Sepharose Fast Flow column (12 cm × 2.5 cm i.d.) equilibrated with the same buffer, 
and eluted with a gradient of 0 to 600 mM NaCl. Fractions containing BfrB were dialyzed 
against 50 mM potassium phosphate buffer (pH 7.6) containing 1 mM TCEP, loaded onto a 
hydroxyapatite Bio-Gel column (10 cm × 2.5 cm i.d.) equilibrated with the same buffer, and 
eluted with a 50 mM to 800 mM potassium phosphate gradient (pH 7.6), 1 mM TCEP. Isolating 
fractions containing BfrB and repeating this chromatographic step a second time yields pure 
BfrB. The separation of 24-mers from incompletely assembled protein was carried out by FPLC 
(AKTA GE Healthcare) in a HiloadTM 16/600 superdexTM 200 pg column equilibrated and 
eluted with 100 mM potassium phosphate (pH 7.0). BfrB purified in this manner is nearly 
devoid of heme. To reconstitute with heme, a previously described method [30] was used with 
some modifications: Hemin chloride was dissolved in 0.1 M sodium hydroxide solution, diluted 
with potassium phosphate buffer (100 mM, pH 7.0) to a final concentration of 1.5 mM. 
Insoluble material was removed by centrifugation. BfrB (3 µM) in 100 mM potassium 
phosphate (pH 7.0) and 1 M NaCl was equilibrated at 80 °C for 1 min in a dry bath (LabDoctor 
Dry Bath Plus), followed by the addition of a first aliquot of heme, which delivered 6 heme 
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molecules per 24-mer BfrB, and the mixture was incubated for 10 min at 80 °C. The 
temperature was then increased to 90 °C prior to addition of a second aliquot of heme delivering 
6 heme molecules per 24-mer BfrB, followed by incubation at 90 °C for 10 min. The 
temperature was then increased to 95 °C prior to addition of a third aliquot of heme delivering 6 
heme molecules per 24-mer, followed by incubation of the mixture at 95 °C for 10 min. The 
resultant mixture was cooled in ice, and loaded onto a HiloadTM 16/600 superdexTM 200 pg 
column equilibrated and eluted with 100 mM potassium phosphate (pH 7.6) at 4 °C. The desired 
fractions were collected and supplemented with 1 mM TCEP. The heme content of BfrB was 
analyzed according to a previously described method [31]. Reconstitution of BfrB with an iron 
core was carried out as reported previously [32]. Upon addition of 500 Fe ions/BfrB the protein 
solutions were incubated overnight at 4 °C and then passed through a superdexTM 200 10/300 
GL column using FPLC (AKTA) to separate them from non-incorporated iron. The content of 
iron in bacterioferritin, before and after reconstitution with an iron core, was measured using a 
previously reported protocol [29, 33].  
BfrB Mutations Crystallization and Data Collection  
All crystallization experiments were conducted in Compact Jr. (Emerald Biosystems) 
sitting drop vapor diffusion plates at 20 °C. Equal volumes of BfrB (10 mg/mL in 100 mM 
potassium phosphate, pH 7.6 and 1mM TCEP) and crystallization solution were equilibrated 
against 75 μL of crystallization solution at 20 °C. For BfrB E81A, crystals displaying a plate 
morphology were obtained in 1-2 days from the Wizard 3-4 screen (Rigaku Reagents) condition 
F12 (2.4 M sodium malonate) . For BfrB L68A, crystals displaying a prismatic morphology 
were obtained in 1-2 days from the Wizard 3-4 screen (Rigaku Reagents) condition E10 (50% 
(v/v) PEG 200, 100 mM Na cacodylate pH 6.5, 200 magnesium chloride).  For BfrB E85A, 
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crystals displaying a plate morphology were obtained in 1-2 days from the Wizard 3-4 screen 
(Rigaku Reagents) condition F4 (15% (v/v) PEG 550MME, 100 mM MES pH 6.5). For 
L68A/E81A, prismatic crystals were obtained in 1-2 days from the Wizard 1 screen (Emerald 
Biosystems) condition D11 (1.26 M ammonium sulfate, 100 mM Tris pH 8.5, 200 mM lithum 
sulfate). Table 3-1 to 3-4 list crystallographic data for BfrB E81A, L68A, E81A/L68A and 
E85A respectively.  
Table 3-1.  Crystallographic data for BfrB E81A refined to 2.50 Å resolution. 
 BfrB E81A  
Data Collection  
Unit-cell parameters (Å, o) a=128.48, b=186.34, c=200.68 
Space group C2221 
Resolution (Å)1 48.85-2.50 
(2.55-2.50) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 537,539 
Unique reflections 83,211 
<I/σ(I)>1 10.6 (1.5) 
Completeness (%)1 100 (100) 
Multiplicity1 6.5 (5.5) 
Rmerge (%)1, 2 17.5 (116.8) 
Rmeas (%)1, 4 19.1 (129.6) 
Rpim (%)1, 4 7.5 (55.4) 
CC1/2 1, 5 0.994 (0.589) 
Refinement  
Resolution (Å) 46.79-2.50 
Reflections (working/test)6 78,989/4,125 
Rfactor / Rfree (%)3 16.5/23.0 
No. of atoms  
(protein/heme/K+/water) 
15,110/301/3/282 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.010 
Bond angles (o) 0.999 
Average B factor (Å2)  





Coordinate error, maximum 0.33 
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likelihood (Å) 
Ramachandran Plot   
Most favored (%) 99.3 
Additionally allowed (%) 0.7 
 
5) Values in parenthesis are for the highest resolution shell. 
6) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for the 
ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
7) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in the refinement. 
8) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[34, 35].  Rpim = precision 
indicating (multiplicity-weighted) Rmerge[36, 37].  
9) CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of 
data [38, 39]. 
10) Friedel pairs were treated as independent reflections for refinement of the anomalous 
scattering atoms.  Therefore, the number of working reflections in refinement is greater than 
the number of unique reflections observed during data scaling. 
 
Table 3-2. Crystallographic data for BfrB L68A refined to 2.20 Å resolution. 
 BfrB L68A  
Data Collection  
Unit-cell parameters (Å, o) a=117.86 Å, b=169.99 Å, c=125.66 Å 
Space group P21212 
Resolution (Å)1 48.43-2.20  
(2.24-2.20) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 869,801 
Unique reflections 126,857 
<I/σ(I)>1 10.7 (2.1) 
Completeness (%)1 99.0 (98.3) 
Multiplicity1 6.9 (7.1) 
Rmerge (%)1, 2 15.3 (121.2) 
Rmeas (%)1, 4 16.5 (130.6) 
Rpim (%)1, 4 6.3 (48.5) 
CC1/2 1, 5 0.997 (0.772) 
Refinement  
Resolution (Å) 48.43-2.20 
Reflections (working/test)6 244,942/12,163 
Rfactor / Rfree (%)3 20.2/26.3 
No. of atoms  15,099/301/3/12/669 
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(protein/heme/Arsenic/Mg2+/water) 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.012 
Bond angles (o) 1.134 
Average B factor (Å2)  






Coordinate error, maximum 
likelihood (Å) 
0.33 
Ramachandran Plot   
Most favored (%) 97.5 
Additionally allowed (%) 2.3 
 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for the 
ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
3) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in the refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[34, 35].  Rpim = precision-
indicating (multiplicity-weighted) Rmerge[36, 37].  
5) CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of 
data [38, 39]. 
 
Table 3-3. Crystallographic data for BfrB E85A refined to 2.55 Å resolution. 
 BfrB E85A  
Data Collection  
Unit-cell parameters (Å, o) a=b=205.56, c=115.77 
Space group P42212 
Resolution (Å)1 48.98-2.55 
(2.60-2.55) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 733,536 
Unique reflections 80,992 
<I/σ(I)>1 10.3 (1.7) 
Completeness (%)1 100 (100) 
Multiplicity1 9.1 (9.4) 
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Rmerge (%)1, 2 21.5 (143.5) 
Rmeas (%)1, 4 22.7 (151.9) 
Rpim (%)1, 4 7.5 (49.5) 
CC1/2 1, 5 0.994 (0.620) 
Refinement  
Resolution (Å) 42.72-2.55 
Reflections (working/test)6 76,947/3,978 
Rfactor / Rfree (%)3 18.0/26.1 
No. of atoms  
(protein/heme/K+/water) 
14,997/301/3/361 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.010 
Bond angles (o) 1.018 
Average B factor (Å2)  





Coordinate error, maximum 
likelihood (Å) 
0.39 
Ramachandran Plot   
Most favored (%) 97.8 
Additionally allowed (%) 2.0 
 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for 
the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
3) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in the 
refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[34, 35].  Rpim = precision-
indicating (multiplicity-weighted) Rmerge[36, 37].  
5) CC1/2 is the correlation coefficient of the mean intensities between two random half-sets 
of data [38, 39]. 
6) Friedel pairs were treated as independent reflections for refinement of the anomalous 
scattering atoms.  Therefore, the number of working reflections in refinement is greater 
than the number of unique reflections observed during data scaling. 
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Table 3-4. Crystallographic data for BfrB L68A/ E81A refined to 1.60 Å resolution. 
 BfrB L68A E81A 
Data Collection  
Unit-cell parameters (Å, o) a=182.2, c=128.5  
Space group H3 
Resolution (Å)1 48.82-1.60 (1.63-1.60) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 1,057,867 
Unique reflections 209,085 
<I/σ(I)>1 10.4 (2.5) 
Completeness (%)1 99.7 (100) 
Multiplicity1 5.1 (5.1) 
Rmerge (%)1, 2 9.7 (63.4) 
Rmeas (%)1, 4 10.9 (70.8) 
Rpim (%)1, 4 4.8 (31.3) 
CC1/2 1, 5 0.995 (0.753) 
Refinement  
Resolution (Å) 34.84-1.60 
Reflections (working/test) 198,565 / 10,492 
Rfactor / Rfree (%)3 17.6 / 20.1 
No. of atoms 
(protein/heme/K+/sulfate/water) 
10,079/172/2/21/1060 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.008 
Bond angles (o) 0.915 
Average B factor (Å2)  






Coordinate error, maximum 
likelihood (Å) 
0.16 
Ramachandran Plot   
Most favored (%) 100 
Additionally allowed (%) - 
 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for the 
ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl. 
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3) Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in the refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[34, 35].  Rpim = precision-
indicating (multiplicity-weighted) Rmerge[36, 37]. CC1/2 is the correlation coefficient of the 
mean intensities between two random half-sets of data [38, 39]. 
 
Measurement of the BfrB-Bfd Binding Affinity by Surface Plasmon Resonance (SPR).  
SPR experiments were performed at 22 °C using a Biacore 3000 instrument (GE 
Healthcare). BfrB was immobilized on a CM5 sensor chip using amine coupling methodology 
[40]: The sensor chip surface was pre-conditioned with 50 mM NaOH, 10 mM HCl, 0.1% SDS 
and 0.085% H3PO4 and activated by injecting 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) in water. The running buffer was PBS 
with 1.5 mM TCEP, pH 7.4. Immobilization of BfrB was carried out by flowing (10 μL/min) a 
100 nM solution of BfrB in 10 mM sodium acetate buffer (pH 5.0) for 32.5 min, followed by 
quenching surface-activated sites not coupled to BfrB by flowing (10 μL/min) 1.0 M aqueous 
ethanolamine-HCl (pH 8.5) for 7 min. A cell activated by NHS/EDC and quenched by 
ethanolamine but not containing BfrB was used as the reference surface, and a cell immobilized 
with bovine serum albumin (BSA) was used as control. To determine the BfrB/Bfd binding 
affinity, a solution of Bfd in 50 mM potassium phosphate (pH 7.0), 150 mM NaCl, 5 mM DTT 
was simultaneously flown (25 µL/min) over the cell containing immobilized BfrB, the reference 
cell, and the cell containing immobilized BSA at 25 µL/min. Bfd solutions with the following 
concentrations were used to construct a binding curve: 0.5 µM, 1 µM, 2 µM, 5 µM, 10 µM, 20 
µM, and 40 µM. The corresponding responses were double-referenced by subtracting the bulk 
refractive index change caused by difference in buffer compositions, as well as by subtracting 
the response from the reference cell. Experiments were conducted in triplicate.  
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Measurement of the BfrB-Bfd Binding Affinity by Isothermal Titration Calorimetry (ITC)  
 Prior to each experiment, BfrB and Bfd were exchanged into 100 mM potassium 
phosphate buffer (pH 7.0), 150 mM NaCl, and 1 mM TCEP by passage through a superdexTM 
200 10/300 GL, or superdexTM 75 10/300 GL column, respectively. ITC was performed at 22 °C 
using a MicroCal auto ITC instrument (GE Healthcare). The cell was loaded with 1.45 mL of 18 
µM Bfd, and titrated with a total volume of 0.25 mL of 20 µM BfrB in 25 injections, each 
lasting 20 s and delivering 10.02 µL, with 300 s between injections. A similar titration of BfrB 
into buffer served as control to measure the heat of dilution. The experiments were repeated 
three times. 
Mobilization of iron from BfrB 
These experiments were carried out in an anaerobic chamber according to a previously 
described method [29] with small modifications: A 1 cm path-length cuvette was filled with a 
solution consisting of BfrB (0.18 µM) reconstituted with 500 ± 20 Fe3+ ions/BfrB, Bfd (0.9 
µM), FPR (7.2 µM) and α,α’- bipyridine (bipy), 3 mM. The reactions leading to mobilization of 
Fe2+ from BfrB were initiated by addition of 1 mM NADPH, and the process was monitored by 
tracking the time-dependent formation of the [Fe(bipy)3]2+complex, which absorbs at 523 nm. 
The percentage of iron released was calculated by normalizing the intensity of the 523 nm band 
to the intensity expected upon mobilization of the 500 iron ions stored in BfrB.  
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RESULTS 
Characterization of the BfrB-Bfd Interaction by SPR  
The X-ray crystal structure of the BfrB-Bfd complex showed that each Bfd binds at the 
interface of a BfrB subunit, near the two-fold axis of symmetry, placing the [2Fe-2S] cluster of 
Bfd approximately 15.1 Å from the heme in BfrB. Studies in solution showed that Bfd binding 
to BfrB makes the BfrB-heme conductive, accelerates reduction of the Fe3+ mineral core and 
facilitates mobilization of Fe2+ [29, 41].  As part of the study reported herein, we investigated 
the binding affinity of the BfrB-Bfd complex using SPR. Figure 3-3A shows the reference- and 
baseline-subtracted responses obtained from flowing Bfd over BfrB immobilized on a sensor 
chip. At each Bfd concentration the corresponding response reaches a plateau, indicating steady 
state equilibrium. Plotting each response at the steady state as a function of Bfd concentration 
results in the hyperbolic binding curve defined by the black circles in Figure 3-3B. The 
interpretive model used to fit these data is described below. 
In SPR experiments BfrB is immobilized on the surface and free Bfd is in the flow. 
Hence, [BfrBf] is the concentration of immobilized BfrB not bound to Bfd, [Bfdf] is the 
concentration of Bfd in the flowing solution, which is maintained constant by the flow system, 
and [BfrB-Bfd] is the concentration of the protein complex at the surface. For a case where Bfd 
binding is homogeneous and the stoichiometry is 1:1, the expression for the dissociation 
constant (Kd) can be written as in equation 1, where the total concentration of immobiled BfrB 
is given by [BfrBt] = [BfrBf] + [BfrB-Bfd]. 
[89:8 − 89;][89:8=] = ?89;@ABC + ?89;@A                                                         (1) 
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Since the X-ray crystal structure showed that Bfd binds to multiple sites on BfrB, equation (1) 
was modified to expression (2), which indicates that n sites in BfrB can be occupied by Bfd, 
with corresponding  dissociation constants.  
[89:8 − 89;] = [89:8 − 89;] + [89:8 − 89;] + ⋯ + [89:8 − 89;E]
= [89:8=]?89;@ABC + ?89;@A + [89:8=]?89;@ABC + ?89;@A + ⋯
+ [89:8=]?89;@ABCE + ?89;@A                                (2) 
The X-ray crystal structure of the BfrB-Bfd complex showed that up to 12 Bfd molecules can 
bind to 12 identical binding sites on BfrB. Thus, assuming that the 12 Bfd binding sites on BfrB 
are identical and non-interacting, expression 2 can be reduced to equation 3 [42], which is 
similar to equation 1, except for the inclusion of the complex stoichiometry, n. 
[89:8 − 89;] = F[89:8=]?89;@ABC + ?89;@A                                                (3) 
At each of the Bfd concentrations ([Bfdf]) used to obtain the sensograms in Figure 3-3A, when 
the system reaches steady state equilibrium (plateau) the concentration of the BfrB-Bfd complex 
at the surface is proportional to the magnitude of the SPR response at the pleateau, which is 
termed Req. Hence, equation 3 can be re-written as equation 4, where R0, corresponds to the 
response when every immobilized BfrB molecule is bound by one Bfd molecule, and the 
remainder terms are defined as above.  
GHI = FG0?89;@ABC + ?89;@A                                                                 (4) 
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 G0 = KLM@CKLM@NM × GPQQR                                                           (5) 
Setting initial values of n = 12 and R0 = 520 ± 18, respectively, and fitting the values of Req 
obtained at each [Bfdf] (circles in the plot of Figure 3-3B) to equation 4,  a Kd value 3.3 ± 0.5 
μM (Table 3- 5), n = 12.7 and R0 = 624 ± 18 were obtained. The initial value of R0 was 
calculated from equation 5 [43], where Rimmo is the SPR response obtained upon immobilizing 
BfrB, MWBfrB is the molecular mass of BfrB (452,672 Da) and MWBfd is the molecular mass of 
Bfd (7,984 Da). As can be seen from the fitted line in Figure 3-3B and from the small residuals, 
the binding curve is well fitted by equation 4. In addition, the linear behavior observed from 
analysis of the binding curve by the Scatchard plot, which is a powerful tool for identifying 
deviations from simple binding models [42, 44], supports the idea implicit in equation 4, that 
the 12 binding sites in BfrB are equivalent and independent. 
 
Figure 3-3 Measuring the affinity of the BfrB-Bfd interaction using SPR. (A) Overlay of 
double referenced sensorgrams resulting from the injection of different concentrations of Bfd 
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(0~40 µM) over immobilized BfrB. (B) The BfrB-Bfd binding affinity determined by steady 
state affinity analysis. Responses at steady state are plotted as a function of Bfd concentrations 
(black circles in the top panel) and fitted to the 1:1 Langmuir model (solid line). The scatchard 
plot is shown in the inset. The residuals plotted in the bottom panel shows the relative response 
difference between the generated fit and the experimental data. 


















3.0 ± 0.5         _   _  _           _         _ 
SPR kinetic 
analysis 
2.6 ± 0.4 0.026 ± 0.002 0.069 ± 0.01 _           _         _ 
ITC analysis 4.0 ± 0.7         _   _ 1.6 ±0.3      30.1 ± 0.7    -7.3 ± 0.1 
      a 
The reported thermodynamic and kinetic parameters obtained from triplicate experiments. 
      b 
Calculated from ∆G = -RTln (1/Kd) 
      c 
Calculated from ∆S =(∆H -∆G)/T 
 
Having shown that the 12 binding sites on a BfrB molecule are identical and 
independent, kinetic analysis of the BfrB-Bfd interaction was carried out assuming the 1:1 
binding model described by equations 6 and 7, where BfrBs indicates one of the 12 binding sites 
in each immobilized BfrB molecule, [BfrBts] is the total concentration of binding sites (12/BfrB 
molecule) on the surface, [BfrBbs] is the concenration of BfrB sites bound to Bfd, ka is the 
association rate constant, and kd is the dissociation rate constant. Equation 7 can be re-written in 
terms of the SPR response as equation 8, where R is the response caused by Bfd binding and 
Rmax is the response when all the binding sites are occupied by Bfd [45]. Hence, values of ka and 
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kd (Table 3-5) were obtained from global fitting of the SPR data to equation 8 (Figure 3-4A) 
with the aid of BIAevaluation software. Note that the ratio of the constants (ka/kd) is very 
similar to the value of Kd obtained from steady state analysis described above, an observation 
that strengthens the conclusion that the Bfd binding sites on BfrB are independent and 
equivalent.  
89:8T + 89; UVW   XYZUV[[\Y] 89:8T − 89;                                                        (6) 
;[89:8_T];` = ab([89:8=T] − [89:8_T])?89;@A − aC[89:8_T]                                     (7) 
;G;` = ab(GQbd − G)?89;@A − aCG                                                (8) 
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Figure 3-4.  Kinetic analysis of the BfrB-Bfd interaction. Top panel: fits generated (black lines) 
by globally fitting the rate equations derived from the 1:1 Langmuir model to the association 
and dissociation phases of all seven injections simultaneously. Bottom panel: the relative 
residual errors from the fits. 
Characterization of the BfrB-Bfd interaction in solution by ITC  
The interaction between BfrB and Bfd was also studied by ITC. The top panel in Figure 
3-5 shows the binding isotherms obtained from titrating Bfd with BfrB, which show that 
formation of the BfrB-Bfd complex is an endothermic process. The ITC data were integrated, 
normalized for nonspecific heat effects, and fitted using a non-linear least square algorithm 
(minimization of χ2) with the aid of the Origin software package provided by MicroCal. Since 
the 12 binding sites on BfrB are equivalent and independent, the data was fitted to the 1:1 
binding model described by equation 6, where the concentration of titrant (BfrB) is the 
concentration of Bfd-binding sites. Fitting the integrated (bottom panel in Figure 3-5) allowed 
us to obtain the ∆H, ∆S, and Kd values listed in Table  3-5, which indicate that the BfrB-Bfd 
association is entropically driven. Note that the value of Kd obtained from these measurements 
is also in good agreement with the Kd values obtained from the SPR experiments, thus providing 
additional support for the idea that the 12 Bfd-binding sites in BfrB are identical and 
independent. 
Below is the deduction of the equations. According to equation (6), at equilibrium, 
?89:8@TA?89;@A[89:8T − 89;] = Bf = 1Bg                                                                           (9) 
Where [BfrBfs] represents free binding sites on BfrB. Equation (9) can be rewritten as: 
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[89:8T − 89;][89;=] = ?89:8@TABf + ?89:8@TA                                                                           (10) 
Where [Bfdt] is the initial total concentration of Bfd in the cell and equals to [Bfdf ]+[BfrBs:Bfd] 
Equation (10) can be rewritten as: 
   Bg = 1Bf = j(1 − j) ?89:8@TA                                                                   (11) 
Where j is the fraction of Bfd bound by protein BfrB binding sites. 
[89:8=T] = ?89:8@TA + Fj[89;=   ]                                                     (12) 
Where [BfrBts] is the total concentration of protein BfrB binding sites, and n is the number of 
binding sites on Bfd. In this case, n=1. Combining equation (11) and (12) gives: 
j − j k1 + [89:8=T][89;=] + 1[89;=]Bgl + [89:8=T][89;=] = 0                                 (13) 
At the beginning of the reaction, the working cell is filled with protein Bfd and the volume of 
the working cell is V0. The working cell is sensed calorimetrically. As BfrB is titrated to the 
cell, the increase of the total volume is ∆V. Because of the total-fill nature of the working cell, 
the increased volume is pushed into the inactive tube. 
Therefore, the heat evolved during the titration process in the working cell is: 
m = j[89:8=T ]no0                                                         (14) 
Where ∆H is the molar enthalpy change of the binding. Therefore, the equation (14) can be 
rewritten as: 
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m =
[M@NMpq ] rstu v[w[xwpq][w[yp]  z{|[w[yp]}~[w[xwpq][w[yp]  z{|[w[yp][w[xwpq][w[yp] 
z
                                       (15)  
After the ith titration, the heat evolved is called Q(i). Since the parameter being measured is the 
heat change upon each injection, therefore, the heat change caused by the ith injection is: 
nm() = m() − m( − 1)                                                                  (16) 
However, the equation (16) assume the total bulk protein concentration of [BfrBts] and [Bfdt] 
remain the same as the initial value by supposing the reaction volume remains V0, not 
considering the added volume of ∆V will cause a dilution of [BfrBts] and [Bfdt]. But in reality, 
although the volume of the working cell sensed calorimetrically remains V0, the real reaction 
volume is V0+∆V. For a certain addition (ith addition), a volume of ∆Vi will be pushed out from 
the working cell into the inactive tube due to the ith addition. However, this part of the solution 
still contributes to the heat effect before it is passed out the working cell. The heat effect caused 
by the displaced volume will contribute about 50% of the heat effect of an equal volume inside 
the working cell, therefore, the equation (16) needs to be modified with the correction factor for 
displaced volume 
nm() = m() − m( − 1) + noPo0 [m() + m( − 1)2 ]                                   (17) 
Where 
rttu [(P)(P) ] is the correction factor for the displaced volume. 
The data was fitted using Origin® scientific plotting software. The fitting process involves initial 
guess of parameters n, KA and H, followed by calculation of Q(i). Q(i) is compared with 
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experimental measured value of evolved heat caused by its corresponding injection. Standard 
Marquardt method is used for the fitting to improve the obtained values of n, KA and H. The 
process is repeated until no further significant improvement in the fitting can be obtained.  
 
Figure 3-5. ITC characterization of the BfrB-Bfd interaction. The top panel shows the raw ITC 
data and the bottom panel shows the plot of integrated area under each titration peak (black 
circle) fitted to the 1:1 Langmuir binding model (solid line). 
Dissecting the Interacting Surface of the BfrB-Bfd Complex. 
The structure of the BfrB-Bfd complex shows that L68, E81 and E85 in BfrB interact 
with M1, Y2 and L5 in Bfd (see Figure 3-2C), forming a contiguous set of interactions that is 
likely to contribute significantly to the stability of the complex. To study the relative 
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contribution of these interactions to the formation of the complex, we prepared the L68A, 
E81A, E85A, L68A/E81A mutants of BfrB, and the Y2A, Y2F, L5A and K40A mutants of Bfd. 
It has been shown that in BfrB, breathing motions of the protein shell link relatively distant 
sections in the structure, and that for example, mutations in some of the pores can affect the 
reactivity of relatively distant ferroxidase centers.[9] The main objective of the mutations 
introduced in BfrB for this study is to determine their effect on the stability of the BfrB-Bfd 
interaction and inhibition of mobilization of core iron stored in the bacterioferritin. 
Consequently, we characterized the BfrB mutants to determine that the mutations, which were 
designed to affect only the BfrB interaction, did not cause significant changes in the structure of 
the protein, or its ability to oxidize Fe2+ and store Fe3+. The biochemical characterization is 
described immediately below, and the structural analysis is presented later. 
Biochemical characterization of BfrB mutants 
The ability of the mutant proteins to assemble into 24-mers was analyzed with the aid of 
a calibrated size exclusion column. The results show that retention volumes exhibited by all the 
mutants are nearly identical to the retention volume displayed by wild type BfrB (Figure 3-6), 
indicating that all mutants assemble into 24-mers. The UV-vis absorption spectrum displayed 
by each of the BfrB mutants is identical to that of wt BfrB (Figure 3-7): The heme in the 
oxidized form gives rise to a Soret band at 418 nm, whereas in its reduced form the Soret band 
is at 425 nm with peaks in the visible at 527 and 567 nm. In wt BfrB, the ratio A280/A418 = 0.67 
is indicative of a 24-mer protein harboring 12 heme molecules [29]. In the UV-vis spectra 
obtained from each of the BfrB mutants the A280/A418 ratio is also ≈ 0.67, indicating that the 
mutants also harbor 12 hemes in a 24-mer assembly. This conclusion is also supported by 
analysis of heme content.  
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Figure 3-6 Elution volumes (Ve) of the BfrB mutants from a calibrated Superdex 200 column. 
BfrB wild type (magenta) 60.2 mL; BfrB L68A 60.4 mL (blue); BfrB E81A (green) 60.3 mL; 
BfrB E85A (cyan) 60.5 mL; BfrB L68A/E81A (orange) 60.7 mL. Inset: A zoomed-in view of 
the elution volumes of the BfrB WT and mutants with calibrated molecular weight. 
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Figure 3-7 Oxidized (black) and reduced (red) spectra of (A) BfrB WT, (B) L68A, (C) E81A, 
(D) E85A and (E) L68A/E81A.  
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The iron oxidation and uptake function of each mutant was evaluated by reconstituting 
each of the proteins with 500 iron ions, while monitoring the process with the aid of UV-vis 
spectrophotometry, as described previously for wt BfrB [26, 27]. The spectral families (Figure 
3-8) obtained from titrating a solution of BfrB with aliquots delivering 50 Fe2+ ions /BfrB show 
a gradual increase in the absorption at 300 nm, which is associated with the growth of ferric 
mineral in the core of ferritin-like molecules [29]. After addition of 500 Fe ions/BfrB the 
solution was incubated overnight at 4 °C and then passed through a Sephadex G-25 column. 
Subsequent determination of iron content in BfrB showed that each of the proteins captured 
>450 Fe ions/BfrB. Having determined that the BfrB mutants assemble into 24-mer molecules 
that are fully functional to oxidize Fe2+ and store Fe3+ in their core, the effect of the mutations 
on the ability of Bfd to bind BfrB mutants and promote the mobilization of core iron was 
examined, and the results are presented below. 
Mobilization of core iron from the BfrB mutants is compromised 
We have previously demonstrated that mobilization of iron stored in BfrB requires Bfd 
[12, 26]. The process of iron mobilization involves Bfd binding to BfrB, which permits electron 
transfer from the [2Fe-2S] cluster in Bfd to the core iron in BfrB via its heme. Consequently, to 
determine the effect of the BfrB mutations on the ability of Bfd to bind and promote the 
mobilization of iron we reconstituted wt and each of the BfrB mutants with 500 ± 20 iron ions 
in their core. The mobilization of iron was monitored by UV-vis in a cuvette containing the 
appropriate mixture of proteins and excess bipy, a Fe2+ chelator. Addition of excess NADPH 
initiates the reactions and the release of Fe2+ from BfrB is monitored by ΔA523, which tracks the 
time-dependent formation of the [Fe(bipy)3]2+ complex. The black circles in Figure 3-9A track 
ΔA523 normalized to the total absorbance change expected on removal of the 500 iron ions in the 
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wt BfrB core, following addition of excess NADPH to a solution containing wt BfrB, FPR and 
Bfd. In comparison, the red circles track ΔA523 on addition of NADPH to a mixture containing 
only wt BfrB and FPR. Clearly, Bfd is necessary for the efficient and quantitative mobilization 
of Fe2+. Similar experiments conducted with the BfrB mutants show that the mutations 
significantly decrease the efficiency of iron mobilization from BfrB: Replacement of Leu68, 
Glu81, or Glu85 for Ala causes significant decrease in the rate of iron release from BfrB, as 
shown by the cyan, green and orange traces in Figure 3-9A, and iron release from the 
Leu68Ala/Glu81Ala double mutant is nearly completely abolished, as shown by the blue trace. 
The accompanying plots in Figure 3-9B track the time-dependent shift of the Soret band 
from 418 nm (oxidized heme) to 425 nm (reduced heme). In the case of wt BfrB, as the reaction 
progresses and the ferric mineral core has been ≈ 80% mobilized, the heme is completely 
reduced, indicating that the flux of electron transfer from Bfd to heme in BfrB is faster than 
electron transfer from the heme to the diminished ferric core. In stark contrast, in the case of the 
E81A/L68A BfrB mutant, the ferric core is not mobilized (Figure 3-9A), and the Soret band 
remains at 417 nm, an observation that is consistent with the idea that E81A/L68A BfrB cannot 
form productive interactions with Bfd, thus inhibiting electron transfer between the [2Fe-2S] 
cluster in Bfd and heme in BfrB. When L68A, E81A or E85A are present in the reaction vessel, 
the corresponding ferric cores are mobilized more slowly than that in wt BfrB, and the steady 
state of reduced heme accumulates more gradually, but it does not reach complete reduction in 
the 60 min that the reactions were monitored. Together, the observations summarized in Figure 
3-9 indicate that the BfrB single mutants undergo productive interactions with Bfd less 
frequently than wt BfrB, and that productive interactions between E81A/L68A BfrB and Bfd 
are extremely rare. 
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Figure 3-8 Iron uptake in (A) WT BfrB (B) BfrB L68A (C) BfrB E81A (D) BfrB E85A (E) 
BfrB L68A/E81A 




Figure 3-9 Bfd facilitated iron mobilization from the wild type and mutant BfrB. (A) Time-
dependent plot of the percentage iron mobilized from BfrB wild type (black), E81A (green), 
L68A (cyan), E85A (orange) and L68A/E81A (blue). The iron release in the absence Bfd is 
shown in red. (B) Time-dependent change in the position of the Soret band during the iron 
mobilization process shown in (A). 418 nm and 425 nm represent fully oxidized and fully 
reduced heme respectively. 
The BfrB mutants have significantly reduced affinity for Bfd 
The findings described in the section above suggest that relative to wt BfrB, the BfrB 
mutants form less stable complexes with Bfd. Experimental support for this idea was obtained 
by measuring the binding constant for the associations between Bfd and each of the BfrB 
mutants using SPR, in a manner similar to that described above for the association between wt 
BfrB and Bfd. Figures 3-10 A-C illustrate the reference- and baseline-subtracted responses 
obtained from flowing Bfd over immobilized L68A, E81A, and E85A BfrB, respectively. For 
each of the mutants, the corresponding response reaches a plateu at each of the Bfd 
concentrations, indicating steady state equilibrium. Hence, the data was fitted to equation 4 to 
time (min)
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obtain the corresponding Kd values. At each concentration of Bfd the corresponding response 
reaches a plateau, indicating steady state equilibrium. Plotting each response at the steady state 
as a function of Bfd concentration produces the binding plots defined by the black (E81A), red 
(L68A) and green (E85A) circles in Figure 3-10E. Fitting the data to equation 4 produced the 
corresponding Kd values (Table 3-5), which indicate that the association between Bfd and L68A 
or E81A BfrB is ≈ 100 times weaker than the corresponding association with wt BfrB, and that 
the E85A mutation results in the lowest affinity for Bfd, which is ≈170 times lower than that 
measured for wt BfrB. In comparison, the reference- and baseline-subtracted responses obtained 
from flowing Bfd over immobilized L68A/E81A BfrB (Figure 3-10D) indicate that the 
association between these two proteins is so low, as to become undetectable by SPR. The 
affinity of Bfd for BfrB decreases in the order wt >>E81A ≈ L68A > E85A >> L68A/E81A 
(Table 3-6), which could be taken to suggest that the efficiency of core iron mobilization should 
follow a similar order. The efficiency of iron mobilization, however, follows the order wt >> 
E81A > L68A ≈ E85A >> L68A/E81A. The explanation for these seeming discrepancies likely 
resides in the fact that biding affinity is not the only determinant for electron transfer between 
the two proteins. Rather, a productive interaction must place the [2Fe-2S] cluster of Bfd in 
relative close (optimum) proximity to the heme in BfrB so that electron transfer is facilitated. 
Consequently, it is possible that although the binding affinity of L68A > E85A, the latter 
undergoes more frequent interactions that are conducive to electron transfer.  
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Figure 3-10 Measuring the binding affinity between Bfd and mutant BfrB by SPR. Overlay of 
double referenced sensorgrams resulting from the injections of different concentrations of Bfd 
(0~ 228 µM) over immobilized BfrB L68A (A), E81A (B), E85A (C) and L68A/E85A (D). (E) 
The steady state affinity fitting plots of Bfd binding to E81A, L68A and E85A are shown in 
black, red and green respectively. 
Table 3-6. Initial iron release rates and binding affinities of wild type and mutant BfrB-Bfd 
interactions 
Protein  Initial Rate (min -1)   Kd (µM) 
Wild Type   0.099 ± 0.007  3.0 ± 0.5 
BfrB E81A  0.031 ± 0.0003  258.5 ± 21.5 
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BfrB L68A  0.019 ± 0.0003  298.5 ± 20.5 
BfrB E85A   0.018 ± 0.0006  590± 2 
BfrB L68A/E81A  0.0038 ± 0.0002  not measureable 
Bfd Y2F  0.097 ± 0.004  3 
Bfd K40A  0.090 ±0.002  12.8 
Bfd L5A  0.044 ± 0.0005  98 
 
X-Ray Crystal Structures of Mutant BfrB 
The structure of the BfrB-Bfd complex showed that Bfd binding to BfrB is accompanied 
by relatively small rearrangements on the BfrB surface [12]. The most significant are the 
reorientation of the L68B, E81A and E85A side chains on BfrB, which enable hydrophobic and 
hydrophilic interactions with Bfd: The closer proximity of the L68 and E85 side chains narrows 
the cleft formed by the two side chains and stabilizes the burial of the Y2 side chain from Bfd 
(Figure 3-11A). The new conformation of the L68 side chain also participates in stabilizing the 
burial of the L5 side chain from Bfd. The side chain reorientations of E81 and E85 also enable 
H-bonding interactions between the backbone carbonyl oxygen of Y2 in Bfd and the carboxylic 
group of E81, as well as the backbone N-H of M1 in Bfd and the carboxylic group in E85. 
These interactions, in turn, allow the side chain of Met1 in Bfd to interact hydrophobically with 
the BfrB surface.  
The X-ray crystal structures of BfrB L68A, BfrB E81A and BfrB E85A show that the 
overall organization of both proteins is nearly identical to that of the wt protein. Close 
inspection of the Bfd-binding site in L68A BfrB (Figure 3-11B) shows that the conformation of 
the E81 side chain remains as in the wt protein, but that the shorter side chain of A68 makes the 
cleft shallower on one side. This is expected to affect the extent of burial of the Bfd Y2 side 
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chain, and also affect the pocket where Bfd L5 anchors on the BfrB surface. The structure of the 
E81A mutant (Figure 3-11C) suggests than in addition to a shallower more open cleft where the 
burial of Y2 from Bfd is likely to be less efficient, a hydrogen bond between the NH of M1 in 
Bfd and a carboxyl O in BfrB E81 is lost. The shorter A85 side chain in the E85A mutant 
(Figure 3-11D) allows the E81 side chain to move away from the cleft and therefore create a 
wider gap, which is likely unfavorable for efficient burial of the Bfd Y2 side chain. In addition 
the hydrogen bonds between NH of M1 in Bfd and the carboxyl oxygens in BfrB E85 are no 
longer possible, which in turn may have an unfavorable effect on how the side chain of M1 in 
Bfd packs against the BfrB surface. In aggregate the E85A mutation eliminates more 
interactions than the L68A or E81A mutations, which is in agreement with the observation that 
the Kd measured for the interaction between Bfd and E85A BfrB is approximately 2-fold larger 
than the Kd values measured for the complexes formed between Bfd and L68A BfrB or E81A 
BfrB. Finally, the structure of the L68A/E81A mutant (Figure 3-11E) shows a very wide cleft, 
where the Y2 side chain in Bfd is unlikely to undergo any meaningful interactions, which is 
likely the reason why the association between Bfd and the double mutant is not measurable, 
which consequently inhibits the mobilization of core iron stored in E68A/E81A BfrB. 
Mutations in Bfd 
The X-ray crystal structure of the BfrB-Bfd complex revealed for the first time the Bfd 
fold, which consists of a helix-turn-helix motif, where the four Cys ligands to iron in the [2Fe-
2S] cluster are located in two hairpin loops (Figure 3-12). It is noteworthy that iron ligands C4 
and C6 are located in the same hairpin loop that contains M1, Y2 and L5, whose side chains 
anchor Bfd on the BfrB surface. We prepared the Y2A, Y2F, L5A and K40A mutants to study 
the effect of these mutations on the effectiveness of the mutants to promote the mobilization of 
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core iron from BfrB, and the stability of the corresponding complexes with BfrB. The Y2A 
mutant cannot form a stable [2Fe-2S] cluster, likely because the Y2 side chain helps stabilize 
the hairpin containing C4 and C6 via packing interactions with G8 and T10 (Figure 3-11). Since 
the Y2A mutant couldn’t be studied, we prepared the Y2F mutant, in an attempt to understand 
the role played by the phenolic OH on Y2 in the stabilization of the BfrB-Bfd interaction. All 
the Bfd mutants (Y2F, L5A and K40A) have similar UV-vis spectroscopic features as the wild 
type Bfd (Figure 3-13). The binding affinity measurements by SPR show that replacement of 
Leu5 to Ala decreases the binding affinity to ~ 98 µM, while the mutation of Lys40 to Ala only 
decrease the binding affinity to ~ 12.8 µM and the mutation of Tyr2 to Ala show a similar 
binding affinity as the wild type protein (Table 3-6). As shown in Figure 3-14 and Table 3-6, for 
mobilization of iron from BfrB, among the three mutations, only L5A causes significant 
decreases in the rate of iron mobilization from BfrB, as shown by the red trace in Figure 3-14. 
The rate of iron mobilization with Y2F or K40A is nearly the same as the wild type Bfd, as 
shown by the black and green traces in Figure 3-14.  
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Figure 3-11. View of wild type BfrB-Bfd interface and the Bfd binding sites on mutant BfrB 
surface. (A) Bfd (cyan) binds to wild type BfrB at the interface of a BfrB subunit dimer (subunit 
A in green and subunit B in gray). BfrB E, L and E interact with Bfd Y2, L5 and M1 
through hydrophobic interactions and electrostatic interactions; O and N atoms are shown in red 
and blue respectively. (B)-(E) The same view as (A) to show the Bfd binding sites on the BfrB 




Figure 3-12. Structural organization of Bfd (PDB 4E6K). Y2 interacts with G8 and T10 to 
stabilize the hairpin containing C4 and C6 (cyan). O, N and S atoms are shown in red, blue and 
yellow respectively.  
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Figure 3-13 UV-vis spectra of Bfd wild type (brown) and mutant Y2F (black), L5A (red) and 
K40A (green) 
 
Figure 3-14 Iron mobilization from BfrB in the presence of Bfd mutant Y2F (black), K40A 
(green) and L5A (red). 




Identification of the hotspot 
Based on the Kd values, the changes in BfrB-Bfd binding free energy (∆∆G) caused by 
the different mutations are shown in Figure 3-15 A and B. The mutation that causes the most 
change in the binding free energy is BfrB E85A, followed by BfrB L68A and E81A, indicating 
the residues E, E, L in BfrB contribute most to stabilize the BfrB-Bfd complex. Bfd L5 
has slightly less contribution than the residues above, yet it still significantly stabilizes the 
BfrB-Bfd complex. In contrast, Bfd K40 has much lower contribution to the binding free energy 
and the phenolic OH on Y2 does not show any stabilization of the BfrB-Bfd complex. The 
residues that have the most contributions to stabilize the complex (interaction hotspot) are 
summarized in Figure 3-15C, where a Bfd molecule (cyan) binds to a BfrB subunit dimer 
between the subunit A (green) and B (gray). A hot region is formed by the hotspot residues 
BfrB E, E, L, Bfd Y2 and L5, which indicates that the cleft and pocket on BfrB where the 
side chains of Y2 and L5 bury to anchor Bfd are essential to the stability of the BfrB complex. 
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Figure 3-15 Identification of hotspot of the BfrB-Bfd interaction. The change in BfrB-Bfd 
binding free energy (∆∆G) caused upon mutation to BfrB and Bfd are shown in (A) and (B) 
respectively. The hotspot residues are highlighted in (C), with O in red and N in blue. 
BfrB-Bfd Binding is an Endothermic Reaction.  
As shown in Table 3-5, the small positive value of ∆H indicates that BfrB/Bfd association is 
endothermic. The negative value of ∆G is contributed by the large positive value of T∆S, 
indicating that the reaction is driven by entropy. The BfrB-Bfd binding, as indicated by the 
crystal structure, is dominated by hydrophobic interactions. Therefore, it is possible that the 
entropy increase is due to the hydrophobic interactions between BfrB and Bfd that cause water 
molecules being released from the binding interface. An analysis of this process is shown in 
Figure 3-16, the binding clefts in free BfrB which are composed by the BfrB Eand L as well 
as by L, P-, N/0, L/, Q/, L// and I/- are occupied with water molecules (Figure 3-16A). 
Binding of Bfd Y2 and L5 to this cleft exclude the water molecules from the cleft to the 
surroundings (Figure 3-16B).  
 
Figure 3-16 X-ray crystal structures of (A) Free BfrB binding cleft filled with water molecules 
(blue sphere) (B) Bfd binding to the BfrB cleft to exclude water molecules to the surrounding 
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CHAPTER IV 
Designing an assay to determine the efficacy of compounds developed to 
inhibit the BfrB/Bfd interaction 
 
Introduction 
As mentioned in Chapter 1, the emergence of multi-drug resistant pathogen strains 
requires discovery of novel targets for antibiotic development. Bacterial iron homeostasis could 
provide such a target. In previous chapters, our studies towards understanding the protein-
protein interactions that regulate the iron homeostasis in Pseudomonas aeruginosa have 
demonstrated that disrupting the BfrB-Bfd interaction could potentially disrupt the intracellular 
iron regulation in bacteria. As a long-term goal, we have initiated an effort towards designing 
drug molecules to disrupt the BfrB-Bfd interaction. Specifically, we are seeking compounds to 
bind BfrB at the Bfd binding site. Consequently, the compounds would displace Bfd binding to 
BfrB; therefore, it would disrupt the BfrB-Bfd interaction.   
Discovery of chemical leads is the first crucial step for discovering potential drug 
candidates [1].  Chemical leads are molecules that have good potency to target mechanisms of 
interest.  There are four most widely used approaches to obtain chemical leads: (1) Carrying out 
modifications on an existing lead or drug [2]. (2) Discovery of a natural product [3]. (3) High 
throughput drug screening (HTS) [4]. (4) Fragment based drug design (FBDD) [1, 5, 6]. 
For our purpose of disrupting the interaction between BfrB and Bfd, the first two 
methods are less feasible due to the unique and novel nature of our target interactions.  HTS is 
currently a dominant method for lead identification used in industry. In this approach, several 
millions of compounds need to be screened against the target of interest. The identified hits are 
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further optimized into chemical leads with desired bioactivity [1, 5]. HTS, however, can be 
expensive due to the requirement of having to screen very large compound libraries. 
In the last decade, FBDD has emerged as a viable alternative to HTS [1, 6-8]. The 
FBDD approach is based on the principle that drug molecules usually contain several 
interconnected functional fragments. The aim of FBDD is to identify the fragments with desired 
bioactivity (called “hits”) and further optimize these hits into chemical leads with high potency 
[1]. Compared to HTS, the advantage of FBDD is that the fragments have a relatively simple 
molecular structure, lower molecular weight (150 kDa ~ 250 kDa), and higher solubility [5, 6, 
9, 10]. In FBDD, typically ~1000 fragments are screened using biophysical approaches, which 
is a much smaller number compared to traditional HTS method [5]. The low chemical 
complexity can simplify the interpretation of the structure-activity relationship, which could 
benefit the later process of fragment optimization [6]. In addition, the simple ligand-receptor 
interaction model shows that fragments give higher hit rates than molecules with more 
complexity, because molecules of more complexity have higher chance to form mismatches 
with proteins through suboptimal interactions [5]. Although as a main disadvantage of FBDD, 
the fragments bind to target proteins with lower affinity, which requires high concentrations of 
soluble fragments, high amount of purified proteins, and high sensitive screening methods.  
Nevertheless, fragments may actually form interactions that are more efficient. Compared to 
binding affinity, ligand efficiency (LE) is a more powerful parameter to evaluate the relative 
optimizability of different sized molecules. LE equals to the free energy of binding divided by 
the number of heavy atoms [11, 12]. For example, given a LE value bigger than 0.3, a weak 
binding fragment (IC50 in mM range) could be carefully optimized into a chemical lead with 
IC50 in nM range [5].  
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Protein-protein interaction “hot spots” are a small number of residues that contribute to 
the vast majority of the stabilizing energy in a protein-protein complex [13]. Ligands that bind 
to target proteins with high affinity have stronger interactions with hot spots on the target 
protein surface, which allow the ligands to be properly oriented at the protein surfcae [6]. This 
idea is well-matched to FBDD approaches, as fragments often form interactions with the hot 
spots, which lead high ligand efficiency [6].  
In chapter 3, three regions on the BfrB-Bfd binding interface were identified as the hot 
spots: (i) the binding cleft on BfrB surface formed by E and L which holds the Bfd Y2. (ii)  
The pocket on BfrB formed by BfrB L, P-, N/0, L/, Q/, L// and I/- which holds the Bfd 
L5. (iii) Bfd amine group in M1 forms hydrogen bonds with carboxyl side chains of E and 
E on BfrB and interacts hydrophobically with BfrB L// L/, I/-, G0 and C-.  The 
identification of the hot spot for the BfrB-Bfd interaction and the structural information of the 
BfrB-Bfd interface have provided basis for designing the fragment library.  
The standard process of FBDD includes establishing a fragment library, screening 
fragments, identifying initial hits, and optimizing the hits to chemical leads [5]. The strategy 
used by our group to find inhibitors to disrupt the BfrB-Bfd interaction is shown in Figure 4-1. 
 
Figure 4-1 Process of finding inhibitors to disrupt the BfrB-Bfd interaction using FBDD. 
 
- 112 - 
 
Among the process in Figure 4-1, my work focused on testing the bioactivity of the 
fragment hits and derived analogs using in vitro functional assay. As mentioned in the previous 
chapters, iron mobilization from BfrB requires interaction between BfrB and Bfd. Therefore, 
the efficiency of iron mobilization from BfrB is a gauge to evaluate the efficiency of the 
potential inhibitors to disrupt the BfrB-Bfd interaction. Ideally, if the fragments/compounds 
compete with Bfd to bind to BfrB, we expect to observe a reduced iron mobilization efficiency 
because of reduced interaction between Bfd and BfrB. 
Two sources of fragments/compounds were tested for their in vitro inhibition effect. The 
first source is a fragment library (FC library) composed of 225 fragments. This library was 
assembled by Dr. Allen B. Reitz from Fox Chase Chemical Diversity Center, Inc., Doylestown, 
Pennsylvania. The library was screened by Dr. Huili Yao in our group, who found that 6 
fragments bind BfrB specifically at the Bfd-binding sites. By soaking crystals of BfrB in 
solutions containing these fragments, the structure of a fragment bound to BfrB was solved by 
Dr. Scott Lovell (Structural Biology Laboratory). The structural information obtained from this 
crystal structure was used to design several analogs with improved binding affinity for BfrB. 
The analogs were synthesized by Baskar Namwalar in Dr. Richard Bunce’s laboratory at 
Oklahoma State University, Stillwater, Oklahoma. As shown in Figure 4-1, I studied the effect 
of both, fragments and analogs, on the inhibition of the BfrB/Bfd interaction. A second source 
of potential inhibitors of the BfrB/Bfd interaction was obtained from a virtual screen of the 
ZINC drugs catalog [14], which was carried out by David Johnson in Dr. John Karanicolas’ 
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Experimental Procedures 
Mobilization of iron from BfrB in the presence of compounds 
In order to explore the inhibition of the BfrB-Bfd interaction caused by the compounds, 
the efficiency of iron mobilization from BfrB was evaluated in the presence of a variety of 
compounds, including the fragments from the FC library, analogs optimized from the 
fragments, and compound hits from the virtual screen of the ZINC library. Prior to the assay, 
the solubility of each compound/fragment in 50 mM potassium phosphate (pH 7.6) containing 
10% DMSO was determined, so that the concentration of each compound could be maximized 
in the assay without compromising its solubility in aqueous buffer. In addition, the pH of the 
buffer containing the maximal concentration of each compound was also measured, so that the 
pH of each mixture could be adjusted to 7.6 prior to starting the assay. 
In an anaerobic chamber, 0.08 µM BfrB (loaded with 500 ± 20 iron), 0.4 µM Bfd and 
3.2 µM FPR (final concentrations) were mixed in a cuvette containing 50 mM potassium 
phosphate (pH 7.6) and 3 mM ferrozine. A small volume of compound dissolved in DMSO 
(stock solution) was added into the cuvette so that the compound reached the desired 
concentration and the total DMSO volume was 10% of the total volume.  The effect of DMSO 
caused the final pH of the solution to be ~ 8. The reaction was initiated by addition of 1 mM 
NADPH and the release of Fe2+ from BfrB was monitored by tracking the time-dependent 
formation of the Fe(II)-ferrozine complex, which absorbs at 562 nm. The percentage of 
mobilized iron was calculated by normalizing the absorbance at 562 nm to the absorbance 
expected upon mobilization of all the iron stored in BfrB. For the compound hits in ZINC 
library, the concentration of FPR was reduced to 2.4 µM and the concentration of the NADPH 
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was reduced up to 0.5~ 0.1 mM.  The control experiment was done by repeating the above 
process but in the absence of the compounds.  
 
Results 
Toward an inhibitor of the BfrB/Bfd interaction 
Results obtained from testing fragment hits from the FC fragment library show that all 
the fragments which bind BfrB at the Bfd binding site do not inhibit the BfrB/Bfd interaction or 
affect the iron mobilization efficiency. This is not surprising, since fragments bind to protein 
surfaces with Kd values between 0.1 and 10 mM [5]. Our attempts at co-crystallizing fragments 
with BfrB showed that one of the fragments (FC996) binds BfrB at the cleft formed by L, P-, 
N/0, L/, Q/, L// and I/- (Figure 4-2A), which is the cleft being identified as the hot spot to 
hold Bfd L5. However, the mobilization of iron stored in BfrB (Figure 4-2B) indicates the 
reaction containing 10 mM FC996 (red) has the same iron mobilization efficiency as the control 
(black). This indicates that the fragment FC996 is not yet potent enough to exert in vitro 
inhibition effects because of its low molecular weight. However, the fact that it binds at the 
BfrB-Bfd interface suggests it has potential to be optimized to a more potent binder. 
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Figure 4-2 (A) Bfd Y2 and L5 insert into the binding pockets on the BfrB surface. (B) Iron 
mobilization from BfrB in the presence of 10 mM FC996 (red) compared to the control (black). 
A series of larger compounds (MW ~ 300 Da) were synthesized by growing the 
structure of FC996 (FC996-optimized compounds). These compounds are less soluble than the 
initial fragments. However, some of them have shown significant inhibition of the BfrB/Bfd 
interaction, assessed by their ability to slow down the mobilization of iron from BfrB. A 
summary of the results is listed in Figure 4-3. In each plot, the efficiency of mobilizing iron 
stored in BfrB in the presence of a given compound is compared with the control, which is the 
iron mobilization reaction in the absence of compound. The black circles track the control and 
the red/green circles track the iron mobilization reaction in the presence of different 
concentrations of compounds. Among all the compounds, BNX111068, BNX111091 and 
BNX111093 show the most significant inhibition effects observed thus far, which are also 
concentration dependent.  
 



























Figure 4-3 Iron mobilization assay in the presence of several analogs designed from the 
structural information obtained in the co-crystal structure of FC996 bound to BfrB (A-V). The 
ID and concentration of the compounds are listed in the right corner of each plot. The black 
trace tracks the control; the red/green traces track each compound at different concentrations. 
For the hits obtained from a virtual screening of the ZINC library, the results are 
summarized in Figure 4-4. Since the assays were carried out with lower concentration of 
NADPH (0.1 ~ 0.5 mM) and FPR (2.4 µM) compared to the experiments above (1 mM NADPH 
and 3.2 µM  FPR), the iron release rates are generally lower for both, the control and the 
reactions in the presence of compound. Nevertheless, the iron mobilization efficiency for a a 
given compound is always compared to the control experiment carried out under the exact same 
conditions. Among all the ZINC compounds, only DJ0010 and DJ0016 show concentration 
dependent inhibition effects. Note that compound DJ 0010 causes the rate of iron mobilization 
to drop ~ 50% at a concentration of 5 mM (Figure 4-4G blue trace), and compound DJ 0016 
causes nearly complete inhibition at 9.0 mM (Figure 4-4J cyan trace).  
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Figure 4-4 Iron mobilization from BfrB in the presence of different compounds identified to 
bind BfrB at the Bfd binding site from an in silico screen of the ZINC database (A-J). The 
largest concentration of compound in each of the plots corresponds to a value close to the 
solubility of the compound in phosphate buffer containing 10% (v/v) DMSO  
 
Discussion 
Factors affecting the BfrB iron mobilization efficiency  
The main challenge of using the assay of mobilization of iron from BfrB as a method to 
detect the in vitro inhibition of the compounds lies in that many factors in the system could 
affect the iron mobilization efficiency, including the molar ratio of the proteins, concentration of 
NADPH, pH, temperature, etc. 
The first parameter we sought to optimize is the molar ratio of Bfd to BfrB in the 
system. Our studies suggested that with a ratio [Bfd]/[BfrB] < 5 and 40-fold excess of FPR, the 
efficiency of iron release shows a dependency on the concentration of Bfd. The higher the ratio, 
the faster the iron release. However, when the [Bfd]/ [BfrB] reaches 5, the rate of iron release 
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reaches its maximum and is not affected by a higher [Bfd]/ [BfrB]. This suggests that for 
facilitating iron mobilization from BfrB, there will be an unnecessary excess of Bfd if the Bfd 
concentration is greater than 5 times of the BfrB concentration in the system. Consequently, the 
excess Bfd would only add to the cost of running the assay. However, if the [Bfd]/[BfrB] <5, 
any slight (pipetting) error in the addition of Bfd and BfrB to the system would cause a change 
in the rate of iron release, which would make the assay less reproducible. Consequently, we 
used [Bfd]/[BfrB] = 5 for all the assays.  
The second parameter is the ratio of [FPR]/[BfrB]. We found that a lower concentration 
of FPR leads to a slower iron mobilization rate. Consequently, lowering the concentration of 
FPR to [FPR]/BfrB < 30 may be beneficial to detect inhibition by weak binders, such as 
fragments. This could be attributed to the idea that reducing FPR concentration would limit the 
electron transfer from NADPH to Bfd. Nevertheless, the data show that as the compounds 
become stronger binders, the functional developed here can be a useful guide to select 
compounds capable of blocking the BfrB/Bfd interaction and therefore preventing the 
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